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Abstract 
Ex vivo engineering of patient T cells for the specific redirection toward cancer cells is 
a promising immunotherapeutic strategy to treat hematological malignancies. In this 
doctoral thesis, a novel CD22 specific chimeric antigen receptor (CAR) was 
generated for the adoptive T cell therapy of CD22 positive leukemia and lymphoma. 
The humanized anti-CD22 (hCD22) single chain variable fragment (scFv) was used 
as antigen binding domain of a third generation CAR, comprising the signal 
transduction domains CD3ζ, CD28 and 4-1BB. Due to its high affinity and biophysical 
stability, the hCD22 scFv was compared to the murine anti-CD22 antibody fragment 
(mCD22) in terms of scFv and CAR stability. Furthermore, to enhance clinical CAR 
efficacy and CAR safety, the hCD22 CAR was optimized by mutagenesis. 
Stability experiments revealed that the mCD22 scFv has a high stability in human 
serum, comparable to its derived hCD22 scFv. CD22 specific activation of T cells 
expressing the corresponding hCD22 or mCD22 CAR proved biophysical stability of 
both scFv derived CARs. 
By mutating the hCD22 CAR human Fc spacer domain (ΔFc), binding to human Fc 
receptor expressing cells was blocked, thus reducing on-target, off-tumor CAR 
related toxicity. The blocking of interleukin-2 (IL-2) secretion caused by the LCK 
mutation introduced in the hCD22 CAR CD28 signaling domain (ΔCD28) needs to be 
further investigated as absence of IL-2 release was observed for both the parental 
and the mutated hCD22 CAR variants. Specific CAR T cell activation was observed 
for the parental, the ΔFc, the ΔCD28 and the double mutated ΔFc-ΔCD28 hCD22 
CAR confirming that both introduced mutations did not affect CAR efficacy in vitro. 
However, the ΔFc-ΔCD28 hCD22 CAR exhibited a slightly lower anti-tumor efficacy 
in comparison to the ΔFc, the ΔCD28 and the parental hCD22 CAR. By additionally 
engineering the hCD22 scFv to further improve the stability of the derived 
ΔFc-ΔCD28 CAR, CAR T cell activation was not enhanced.  
This doctoral thesis provides the basis for the clinical development of a novel CD22 
CAR T cell therapy for the treatment of CD22 positive leukemia and lymphoma.  
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Zusammenfassung 
Die Modifikation von Patienten-T-Zellen ex vivo zu deren spezifischen Ausrichtung 
gegen Krebszellen ist eine vielversprechende immuntherapeutische Strategie zur 
Behandlung von hämatologischen Neoplasien. In dieser Doktorarbeit wurde ein 
neuartiger CD22-spezifischer chimärer Antigenrezeptor (CAR) zur adoptiven T-Zell-
Therapie von CD22-positiven Leukämien und Lymphomen generiert. Das 
humanisierte anti-CD22 (hCD22) scFv-Fragment (single chain variable fragment) 
wurde als Antigenbindungsdomäne eines CARs der dritten Generation, der die 
CD3ζ-, CD28- und 4-1BB-Signaltransduktionsdomäne enthält, integriert. Aufgrund 
dessen hohen biophysikalischen Stabilität wurde das hCD22-scFv mit dem murinen 
anti-CD22-Antikörperfragment (mCD22) hinsichtlich der scFv- und CAR-Stabilität 
verglichen. Darüber hinaus wurde der hCD22-CAR durch Mutagenese optimiert, um 
die CAR-Wirksamkeit und -sicherheit zu optimieren. 
Stabilitätsexperimente zeigten, dass das mCD22-scFv eine hohe Stabilität in 
humanem Serum aufweist, die mit dem abgeleiteten hCD22-scFv vergleichbar ist. 
Der Nachweis der biophysikalischen scFv- und CAR-Stabilität erfolgte durch die 
CD22-spezifische Aktivierung der hCD22- bzw. mCD22-CAR tragenden T-Zellen. 
Durch Mutation der humanen Fc-Spacer-Domäne (ΔFc) des hCD22-CAR wurde die 
Bindung an Fc-Rezeptor-exprimierenden Zellen geblockt und so die unspezifische 
CAR-Toxizität reduziert. Das durch die LCK-Mutation in der CD28-Signaldomäne 
(ΔCD28) verursachte Blockieren der Interleukin 2 (IL-2)-Sekretion muss weiterhin 
analysiert werden, da sowohl bei den T-Zellen mit den mutierten als auch den 
parentalen hCD22-CARs keine IL-2-Freisetzung beobachtet wurde. Die spezifische 
CAR-T-Zell-Aktivierung mittels parentalem, ΔFc, ΔCD28 und doppelt-mutiertem 
ΔFc-ΔCD28 hCD22-CAR bestätigte, dass die beiden eingefügten Mutationen die 
CAR-Wirksamkeit nicht beeinflussen. T-Zellen mit dem ΔFc-ΔCD28 hCD22-CAR 
zeigten eine minimal geringere antitumorale Wirksamkeit im Vergleich zu denjenigen, 
die den ΔFc, ΔCD28 und parentalen hCD22-CAR trugen. Durch die zusätzliche 
Modifikation des hCD22-scFv zur Erhöhung der Stabilität des ΔFc-ΔCD28 CAR 
wurde die T-Zell-Aktivierung nicht verbessert. Diese Doktorarbeit liefert die 
Grundlage zur klinischen Entwicklung einer neuartigen CD22-CAR-T-Zell-Therapie 
zur Behandlung CD22-positiver Leukämien und Lymphome.   
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1 Introduction 
1.1  Antibody based therapy 
1.1.1 Monoclonal antibodies and antibody fragments 
Nowadays, therapeutic monoclonal antibodies (mAbs) constitute the largest and 
fastest growing class of biopharmaceuticals. Due to their specific interaction with 
pathogens and immune cells, their biophysical stability and their long half-life, they 
are regarded as very powerful (Jefferis, 2012). 
More than a century ago, first suggestions to use antibodies for the elimination of 
tumor cells and pathogens emerged with Paul Ehrlichs “magic bullet” concept 
(Strebhardt and Ullrich, 2008). However, it is only since the discovery of hybridoma 
technology in 1975 that mAbs of murine origin, directed against specific antigens, 
could be generated. As they are produced by a single cell clone and have the same 
amino acid sequence, monoclonal hybridoma-derived antibodies are characterized 
by their identical affinity and specificity (Kohler and Milstein, 1975). However, adverse 
events rapidly occurred after their clinical application in patients. Because of their 
murine origin, high immunogenicity induced by the development of human anti-
murine antibodies (HAMA) could be observed (Kim et al., 2005). To reduce the 
immunogenicity, murine constant domains of the heavy and light chains were 
replaced with human counterparts by genetic engineering to form so-called chimeric 
antibodies (Morrison et al., 1984) (Figure 1). By additionally replacing the murine 
framework regions of the variable domains with human amino acid sequences, the 
murine components are even more reduced, leading to humanized antibodies 
(Krauss et al., 2003a). Methods such as phage display or transgenic mice even 
permit the generation of fully human antibodies (Ribatti, 2014) (Figure 1). 
Immunoglobulins (Ig) are divided into five distinct subclasses (isotypes): IgA, IgD, 
IgE, IgG and IgM. Nevertheless, only IgG class antibodies are currently used for 
therapeutic purposes (Redman et al., 2015; Reichert, 2017). An IgG (150 kDa) is 
composed of two identical light and two identical heavy chains, covalently connected 
by multiple disulfide bridges. While a light chain comprises one constant domain (CL) 
and one variable domain (VL), a heavy chain consists of three constant domains 
(CH1-CH2-CH3) and one single variable domain (VH) (Kim et al., 2005). From 
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a functional point of view, an IgG is separated into one single crystallizable constant 
fragment (Fc) connected via a flexible hinge region to two identical antigen-binding 
fragments (Fabs) (Kim et al., 2005). Each variable domain of a Fab contains three 
hypervariable complementary-determining regions (CDRs) flanked by four framework 
regions. While these regions are responsible for specific and high affinity antigen 
binding, the Fc region mediates the effector functions (Pandey and Mahadevan, 
2014) (Figure 1). 
 
Figure 1: Schematic representation of a murine, chimeric, humanized and human monoclonal 
IgG antibody. Grey: murine amino acid sequences; light green: human amino acid sequences; black: 
murine CDRs; dark green: human CDRs. Adapted from Kim et al., 2005. 
 
MAbs feature a long half-life but show poor tumor penetration due to their high 
molecular weight (Yokota et al., 1992). These undesired properties have been 
circumvented thanks to the generation of small antibody fragments by enzymatic 
digestion of IgG. Indeed, digestion with the protease papain allowed to obtain 
a monovalent Fab fragment (50 kDa) which consists of a VL and a VH domain as well 
as a CL and a CH1 domain of the original mAb (Figure 2). The smallest antibody 
fragment able to preserve the antigen binding ability is the variable fragment (Fv) 
composed of the VL and VH domains (Essig et al., 1993). When these variable parts 
are connected via a short, engineered peptide linker of 14 to 25 amino acids, 
a so-called single chain variable fragment (scFv) of about 25 kDa is formed (Bird et 
al., 1988; Essig et al., 1993). When associated by a disulfide bond, a disulfide-bond 
stabilized Fv (dsFv) is created. The small-sized scFv and Fab fragment consistently 
conserve the specific binding affinity of the entire antibody and present an improved 
tumor penetration and a faster blood clearance (Essig et al., 1993; Yokota et al., 
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1992). Besides monovalent fragments, multivalent antibody fragments can also be 
generated, for example by reducing the size of the flexible linker (Frenzel et al., 
2013). The bivalent diabody (Db) is a representative example for this purpose 
(Figure 2).  
 
Figure 2: Schematic representation of different recombinant antibody formats. Grey: constant 
domains; green: variable domains. Adapted from Frenzel et al., 2013. 
 
1.1.2 Mechanism of action  
Therapeutic antibodies that specifically target tumor associated antigens (TAA) can 
attack the tumor cells through either direct and/or indirect mechanisms of the immune 
system. By binding a TAA, an antibody can directly impact the downstream signaling, 
acting either as an antagonist or an agonist by respectively inhibiting or modulating 
the induced signal transduction. For example, Rituximab, a chimeric antibody, directly 
induces apoptosis by binding the cluster of differentiation 20 (CD20) (Johnson and 
Glennie, 2003). 
To specifically lyse tumor cells, mAbs can also activate other components of the 
immune system through their Fc fragment. By interacting with Fcγ receptor 
expressing cells, the antibody indirectly triggers antibody-dependent cell-mediated 
cytotoxicity (ADCC). Complement dependent cytotoxicity (CDC) occurs after 
interaction between the Fc fragment and the C1q protein which activates the 
complement (Redman et al., 2015). 
Besides these indirect antitumor effector functions, mAbs, but also scFvs, can be 
conjugated to cytotoxic effector substances, for example enzymes, toxins, 
radionuclides or cytokines which transmit extended artificial effector functions 
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(Schrama et al., 2006). Resulting conjugates or fusion proteins are called 
immunotoxin, immunoRNase, immunocytokine or radioimmunoconjugate, depending 
on their added effector. This strategy can enhance the therapeutic impact. 
Advances in antibody engineering and design led to new approaches using T cells 
and their effector functions against tumor cells (Satta et al., 2013; Stamova et al., 
2012). Bispecific antibodies (BsAbs) and chimeric antigen receptors (CARs) are 
adaptor molecules combining specific TAA recognition with potent T cell attack 
mechanisms. In one single molecule, BsAbs possess the specificity of two 
antibodies. Bispecific T cell engagers (BiTE) contain two scFvs, one targeting a TAA 
and another targeting CD3 on T cells. In this way, T cell activation is triggered 
independently of the T cell receptor (TCR) specificity, leading to the release of 
granzyme B and perforin and consequently to tumor cell lysis (Baeuerle and 
Reinhardt, 2009; Satta et al., 2013). In CARs, a TAA specific scFv is directly fused 
with the signaling part of a TCR and expressed on the surface of T cells. This 
enables the activation of T cell effector functions in a major histocompatibility 
complex (MHC) independent manner (Satta et al., 2013; Wu et al., 2016). 
 
1.2 Adoptive T cell therapy 
Despite major advances in the field of monoclonal antibodies, their therapeutic 
application in different formats is often limited due to short half-life, insufficient tumor 
penetration and frequent reactivity with normal tissue. Newly acquired knowledge 
regarding immunology and oncology permit the development of an increasing 
number of adoptive immunotherapy strategies to treat cancer. The goal of the 
adoptive cell therapy (ACT) is to arm T lymphocytes from patients with a specific 
reactivity against tumor associated antigens (TAA) to trigger an immune response 
leading to targeted tumor cell lysis. To achieve this, highly active, tumor specific 
lymphocytes are isolated, genetically modified ex vivo and expanded before 
a subsequent autologous administration into patients (Figure 3). In this way, antibody 
based approaches have emerged for the development and use of antigen specific 
T lymphocytes (Dudley and Rosenberg, 2003; Rosenberg et al., 2008). 
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Figure 3: Schematic representation of the adoptive cell therapy. T cells isolated from tumor 
patient blood are genetically modified ex vivo by lentiviral vectors encoding for a TCR or a CAR which 
confers specificity against cancer cells. Subsequently, the modified T cells are expanded ex vivo and 
re-infused back into the patient after lymphodepletion. 
 
In contrast to mAbs, tumor infiltrating lymphocytes (TILs) isolated from human tumor 
tissue have the capacity to actively penetrate tissue. Clinical effectiveness of ACT 
was seen when using autologous TILs to treat patients with metastatic melanoma 
(Dudley et al., 2002; Muul et al., 1987; Rosenberg et al., 1994). After ACT, the anti-
tumor reaction maintained by these TILs led to a repeated immune reaction with 
cytotoxic activities against tumor cells and consequently to tumor regression. An 
important improvement of the therapeutic efficacy of ACT was obtained through 
lymphodepletion prior to CAR T cell infusion (Dudley et al., 2002). Indeed, by 
depleting regulatory lymphocytes prior to the administration of TILs and interleukin-2 
(IL-2) infusion, the anti-tumor T cell expansion in patients was enhanced.  
Nevertheless, the complex, time consuming TIL preparation and culture from tumor 
tissue remain a challenge and the therapeutic application is consequently limited. 
Protocol optimizations concerning the stimulation and cultivation of tumor specific 
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TILs were continuously performed (Dudley et al., 2003). Partial or complete 
remissions were observed for more than 50% of patients with refractory metastatic 
melanoma after a combinatorial therapy including lymphodepletion followed by TIL 
ACT. Besides cancer regression, proliferation of TILs with unknown tumor specificity 
lead to autoimmune reactions in some patients (Dudley et al., 2005). To avoid this 
unwanted T cell autoreactivity and potential cross-reactivity with antigens on healthy 
tissue, it would be preferable to use T cells with a defined specificity.    
The specificity of a T cell is determined by the T cell receptor (TCR). Advances in 
genetic engineering of T cells and in gene transfer techniques enabled the transgenic 
expression of a recombinant TCR on the surface of engineered T lymphocytes 
(Morgan et al., 2006). By selectively recognizing a defined TAA, the recombinant 
TCR induces enhanced tumor cell killing. However, the target recognition of an 
engaged TCR is dependent on the MHC complex, present on targeted cells. As part 
of the tumor immune escape machinery, dysregulation in MHC antigen processing 
and presenting mechanisms occur frequently in tumors (Seliger et al., 1997). 
Therefore, TCR engineered T cells often do not recognize tumor cells, limiting their 
application (Garcia-Lora et al., 2003). Furthermore, cell surface antigens such as 
glycolipids or carbohydrates are expressed on many tumor cells without MHC 
presentation and cannot be recognized by TCRs. To overcome these limitations, the 
engineering of T cells that express antibody based chimeric antigen receptors 
appeared to be a promising strategy. 
 
1.3 Chimeric antigen receptor: structure, function, challenges 
In the early 1990s, pioneering work demonstrated the redirection of T cell specificity 
and function by a chimeric antigen receptor (CAR), a recombinant receptor 
combining a scFv with a T cell signaling domain (Eshhar et al., 1993; Gross et al., 
1989). Nowadays, CARs emerged as a novel and powerful therapy for hematological 
malignancies. A CAR consists of four regions: an extracellular antigen binding 
domain, a spacer or hinge domain, a transmembrane region and an intracellular 
signaling domain (Dotti et al., 2014; Sadelain et al., 2013) (Figure 4).  
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Figure 4: Schematic representation of the chimeric antigen receptor (CAR) structure. CARs 
target TAAs in a MHC-independent manner and consist of one scFv as targeting moiety, one spacer 
domain, one transmembrane domain and one or more signaling domains. First generation CARs 
contain one single cytoplasmic activation domain. Second and third generation CARs have one or two 
additional co-stimulatory domains. 
 
The extracellular part commonly corresponds to a scFv, derived from the binding 
region of a monoclonal antibody. A CAR will thus have the affinity and specificity of 
the chosen antibody fragment. These artificial receptors mainly recognize TAAs but 
they can also bind non-classical T cell antigens independently of MHC as for 
example gangliosides and carbohydrates. While a high binding affinity predicts an 
efficient CAR T cell activation, studies revealed that when a certain affinity threshold 
is obtained, the CAR T cell activation is not further improved (Chmielewski et al., 
2011). Beside affinity, the spatial position of the epitope also impacts CAR function 
(Hombach et al., 2007). The CAR mediated T cell activation is affected and 
modulated by the origin, the flexibility and the size of the spacer domain located 
between the scFv and the transmembrane domain (Maus et al., 2014). Commonly 
used hinges are IgG1 derived Fc, CD8 and CD28 spacer regions (Gacerez et al., 
2016). By optimizing the distance between the tumor and the T cell, the provided 
flexibility enables, for some CARs, more efficient target binding and a stable 
expression on the surface of T cells (Guest et al., 2005a). Depending on the number 
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of domains within this cytoplasmic moiety, CARs are classified into three generations 
(Gacerez et al., 2016) (Figure 4). However, the optimal intracellular configuration still 
remains an open issue. The intracellular TCR derived signaling region, composed of 
one or more domains, triggers T cell activation upon antigen recognition (Figure 5). 
Following phosphorylation of the immunoreceptor tyrosine-based activation motifs 
(ITAMs) of the signaling region, a downstream signaling cascade is initiated, resulting 
in CAR T cell amplification, cytokine secretion and cell killing activity. 
 
Figure 5: CAR mechanism of action. Upon CAR interaction with the cognate antigen via the 
extracellular antibody fragment, an intracellular downstream signaling cascade is initiated, resulting in 
CAR T cell amplification and cytokine release which subsequently trigger a MHC-independent tumor 
cell lysis. 
 
First generation CARs present a scFv as binding moiety linked to an activation 
domain by a transmembrane portion, the TCR derived CD3ζ chain (Figure 4). This 
single cytoplasmic domain initiates signal transduction upon CAR antigen binding. 
While potent in vivo, several clinical studies revealed that the therapeutic efficacy of 
first generation CARs is limited due to poor persistence of CAR T cells, caused by a 
transient activation (Kershaw et al., 2006; Till et al., 2008). Significant progress was 
achieved by adding, besides the activation portion, one or two co-stimulatory 
domains resulting in a second or third generation CAR, respectively (Figure 4). These 
moieties are either derived from CD28, the most common and well-studied 
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co-stimulatory receptor, or from tumor necrosis factor (TNF) receptor family members 
involved in normal T cell activation, like OX40 (CD134) or 4-1BB (CD137). The 
addition of these domains enhances the CAR potency, resulting in full T cell 
activation and in improved tumor attack. Cytokine secretion as well as CAR T cell 
amplification and persistence are enhanced by the presence of these co-stimuli 
(Finney et al., 1998; Hombach et al., 2001a). 
Each co-stimulatory domain induces distinct T cell effector functions, although a few 
overlaps exist (Abken, 2014). While they all increase the secretion of 
interferon γ (IFNγ), interleukin-2 (IL-2) release is only triggered upon CD28 
co-stimulation but not upon 4-1BB or OX40. Amplified cell killing activity, enhanced 
T cell persistence and expansion is observed for CD28 containing CARs compared to 
other second generation CARs harboring 4-1BB or OX40 (Hombach and Abken, 
2011). However, T cell amplification is also triggered more efficiently by 4-1BB than 
by OX40. Cell survival and activation induced cell death (AICD) is prevented by 
4-1BB signaling (Gacerez et al., 2016). OX40 is considered to be a late 
co-stimulatory molecule which enables the induction of memory T cells that can 
escape AICD (Hombach and Abken, 2011).  
Currently, second generation CARs are the most investigated format and are widely 
used in clinical trials. Because little advantages were found in vivo with third 
generation CARs, only a few of these CARs are tested in the clinic (Gacerez et al., 
2016). The modular CAR architecture, including binding and signaling moieties, 
allows a large variety of possible combinations. As each region individually 
contributes to the receptor characteristic, there is no single optimal CAR 
configuration. 
Using CAR modified T cells for cancer immunotherapy provides several advantages. 
CARs are equipped with antibodies specifically recognizing cognate antigens, mostly 
TAAs, independently of MHC processing and presentation. This offers the possibility 
to target a variety of non-classical T cell antigens, including gangliosides and 
carbohydrates, without excluding MHC presented antigens such as the HLA-A*0201 
presented NY-ESO1 peptide (Stewart-Jones et al., 2009). Tumor escape by 
downregulating the number of extracellular human leucocyte antigen (HLA) 
molecules or by introducing defects in antigen processing can be overcome by 
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MHC-independent binding (Curran et al., 2012). A broad range of patients can 
therefore be treated with CAR T cells, regardless of their HLA type. The modular 
CAR design enables the fusion of one or more signaling domains. In this way, CAR 
T cells have, besides improved effector T cell functions, the ability to induce memory 
T cell phenotypes. 
Although the clinical efficacy of CAR T cells has already been proven in 
hematological malignancies, some major challenges have still to be considered for a 
broader use in the clinic. CAR toxicity is a major concern and increasing the clinical 
safety of CAR T cell based therapies remains a priority. On-target, off-tumor activity 
resulting in the destruction of normal tissues and cytokine storms associated with 
important immune responses are the two main forms of CAR T cell toxicity. 
A prominent example of on-target, off-tumor toxicity is B cell aplasia induced by 
CD19 CAR T cells (Brentjens et al., 2011a; Kochenderfer et al., 2012a). Although this 
can be managed by intravenous injection of immunoglobulin, such damages might 
not be prevented in other cases. Therefore, identifying and selecting highly specific 
tumor targets is essential (Sadelain et al., 2013). For CAR T cells, an ideal antigen is 
homogenously expressed on tumors but not on healthy tissues. Unlike other side 
effects, toxicity in form of cytokine release syndrome cannot be controlled by 
reducing the dosage of CAR T cells, as once administered, they continue to 
proliferate.  
Within this context, new safety mechanisms to control CAR activity and to prevent 
these toxicities are more and more emerging. Systems including combinatorial CARs, 
dual CARs or switchable CARs are created to regulate CAR T cell activity in a spatial 
and temporal way (Gacerez et al., 2016; Maus and Powell, 2015). Furthermore, 
advances in CAR design allow to reduce toxicity while improving CAR efficacy by 
introducing the inducible caspase 9 fusion protein (Maus and Powell, 2015) or 
mutations as for example in the human Fc spacer or in the co-stimulatory CD28 
domain.  
The IgG1 Fc spacer domain, located between the antibody fragment on the 
extracellular site and the transmembrane domain of the CAR, seem to be required for 
the stable and efficient activation of several CD3ζ CAR expressing T cells (Guest et 
al., 2005b; Moritz and Groner, 1995). However, unintentional spacer binding to IgG1 
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Fc receptors of innate immune cells causes off-target activation of CAR T cells 
(Hombach et al., 2010). In this case, CAR T cells are activated independently from 
their target, resulting in monocyte and natural killer cell lysis as well as in cytokine 
release. Mutation of the PELLGG and ISR motif corresponding to the Fcγ receptor 
(FcγR) binding domain and localized in the CH2 region of the spacer domain 
prevents unspecific CAR T cell activation by FcγR expressing cells  (Hombach et al., 
2010).  Upon antigen binding, CAR T cell mediated immune responses are 
suppressed by tumor infiltrating regulatory T (T reg) cells, resulting in a less efficient 
tumor attack (Kofler et al., 2011). The negative impact of T reg cells on the clinical 
response of adoptive immunotherapy remains a problem (Yao et al., 2012). 
Lymphodepletion prior to CAR T cell treatment enables the elimination of T reg cells, 
resulting in a better engraftment and CAR T cell persistence (Dai et al., 2016). 
However, for the efficiency of CAR therapy, their regulation at a low level might be 
essential to obtain long-term CAR activity. Mutation of the LCK binding domain 
localized in the CD28 co-stimulatory region enables to block the IL-2 secretion 
induced by activated CAR T cells which is responsible for the proliferation and the 
suppressive activity of T reg cells. This led to an enhanced anti-tumor response even 
in the presence of T reg cells (Kofler et al., 2011). To elucidate the complexity of CAR 
downstream signaling, a broader understanding of how each region contributes to 
the overall CAR activity is necessary. Another challenge is the complex clinical 
management of CAR T cell therapies. The ex vivo manipulation of autologous patient 
T cells is an expensive process, but allows very personalized therapies. 
 
1.4 Leukemia  
1.4.1 Hematological malignancies 
Neoplasms of hematopoietic and lymphoid tissues are malignant proliferations which 
can emanate from each and every B and T cell development stage (Piper, 2012). 
According to the current WHO classification of 2008, lymphoid neoplasms are 
classified based on their morphological, immunological, molecular and cytogenetic 
profile as well as their clinical characteristics (Campo et al., 2011). Depending on 
their localization (blood, lymph nodes or other lymphatic tissue), hematological 
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malignancies are referred to as leukemia, lymphoma or extranodal lymphoma (Piper, 
2012). 
Leukemia originates from the bone-marrow. Depending on the disease progression, it 
can be characterized as acute or chronic and, according to the myeloid or lymphoid 
origin, classified into acute lymphoblastic leukemia (ALL), chronic lymphoblastic 
leukemia (CLL), acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). 
In 2012, 13 new leukemia cases out of 100 000 individuals were diagnosed in 
Germany [A]. CLL was diagnosed in more than one third of all leukemia cases. The 
incidence of leukemia is higher for men in comparison to women. One out of 67 men 
and one out of 91 women develop leukemia during their life time [B]. Depending on 
the type of leukemia, the affected age group is different. While CLL mainly affects 
elderly people, ALL is the most common cancer in children, especially under 5 years 
of age. However, ALL can occur at any age and the risk continually increases at an 
age of over 30 years (Piper, 2012) [B]. 
CLL, the most common type of leukemia, is a very heterogeneous disease. Despite 
the availability of various potent treatments, CLL cannot be cured with conventional 
therapies. Even after complete remission, the high risk of relapse results in a poor 
prognosis for patients with relapsed and refractory CLL (Porter et al., 2015). In 2012, 
the incidence of pediatric ALL patients in Germany was around five cases out of 
100 000 children under five years (Piper, 2012). Combined chemotherapies cured 
80-85% of children with ALL but for those who experienced relapsed and refractory 
disease (15-20%), the prognosis is very poor and the therapy was truly effective for 
only 30-50% of them (Locatelli et al., 2012). However, while success of 
chemotherapy is observed for pediatric ALL, this is not the case for adults. Despite a 
high initial complete remission rate, relapse often occurs and the overall five year 
survival rate is about 30% (Ai and Advani, 2015). Indeed, at five years after relapse, 
long term remission remains only at around 7% (Dinner et al., 2014). 
 
1.4.2 Current therapy options 
Although significant progress was made in treating CLL, the disease remains 
incurable. The current standard treatment consists of a chemotherapy using 
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fludarabine in combination with cyclophosphamide enabling a complete remission of 
69% of treated CLL patients (Piper, 2012). Using Rituximab, an anti-CD20 
monoclonal antibody, in addition to the previous chemotherapy treatment enhances 
the outcome (Tam et al., 2008). In many cases the disease progression is inevitable. 
The bone marrow transplantation remains the only potential curative treatment 
although the risk of mortality is high (Piper, 2012). While the use of 
immunochemotherapy increases the overall response rate of CLL patients, there is 
an urgent need to develop strategies for a long term tumor cell elimination.  
The current treatment for ALL consists of a chemotherapy regimen in four steps. 
Depending on the risk of treatment failure, the therapy intensity varies (Cooper and 
Brown, 2015; Piper, 2012). The first part is a remission induction therapy which aims 
to induce complete remission by eliminating the leukemia cells. For patients with 
induction failure, an allogeneic bone marrow transplant might be an option. The 
following step is the consolidation phase to remove the residual tumor cells whereas 
the central nervous system (CNS) prophylaxis is used for ALL eradication from the 
CNS. The final maintenance regimen lasts over two to three years and reduces the 
risk of relapse (Cooper and Brown, 2015; Piper, 2012). Allogeneic hematopoietic 
stem cell transplant (HSCT) is indicated for adults and children with delayed 
remission (over four weeks) presenting high relapse risk or refractory disease who 
cannot be rescued with standard chemotherapies. The low cure rates with HSCT 
range between 10 to 30% (Dinner et al., 2014). As for CLL, there is an obvious need 
to find new therapies to improve the outcome of ALL in children and adults. 
 
1.4.3 CAR based therapies  
In the context of enhancing the overall cure rates for CLL and ALL patients, antibody 
based therapies represent a promising strategy. Indeed, targeting antigens to 
activate the immune system either by single agents or in combination with 
chemotherapy to eliminate leukemia is of growing interest (Dinner et al., 2014; 
Koehler et al., 2012). The use of immunotherapy offers new mechanisms of action 
and different side effect profiles. The clinical application of monoclonal antibody 
based therapies including Rituximab and Epratuzumab, an anti-CD20 and anti-CD22 
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monoclonal antibody, respectively, improved the overall survival of CLL and ALL 
patients (Ai and Advani, 2015; Annesley and Brown, 2015; Koehler et al., 2012).  
The chimeric antigen receptor based therapy represents another rational and 
promising approach to overcome the poor prognosis of patients with relapsed and 
refractory leukemia. CD19 is the most investigated target for CAR T cell therapy. 
Recent successful Phase I clinical trials with CD19 CAR therapy show promising 
results in the treatment of leukemia (Oluwole and Davila, 2016). For relapsed and 
refractory ALL, 67 - 90% of patients achieved a complete remission (Oluwole and 
Davila, 2016). Complete and long-term remission was also obtained for refractory 
CLL patients (Kalos et al., 2011). Autologous patient T cells were therefore 
genetically modified ex vivo with a CAR specific for CD19, leading to their redirection 
toward tumor cells once injected back into the patient. The efficacy of CAR T cell 
therapy is enhanced by prior lymphodepletion which prepares a favorable 
environment for the transduced T cells (Gattinoni et al., 2006).  
Besides the clinical success of CAR therapy, related treatment toxicity remains 
challenging and several multicenter Phase II clinical trials are currently investigating 
clinical CAR efficacy and safety (Oluwole and Davila, 2016). While B cell aplasia, 
observed in all treated patients, can be managed by lifelong immunoglobulin 
replacement, further on-target, off-tumor toxicity and cytokine release can lead to 
adverse effects with severe complications. Furthermore, as CAR T cells target one 
specific antigen, this selective pressure induces loss of the target as seen after CD19 
CAR T cell treatment of ALL (Grupp et al., 2013). Controlling these side effects is a 
requirement for the establishment of CAR T cell therapy as a powerful treatment 
regimen to cure hematological malignancies. 
Despite the success of CD19 CAR T cell therapy, new antigens need to be found to 
develop alternative CAR T cell treatments for patients with CD19 negative 
hematological malignancies. Several ongoing Phase I clinical trials are investigating 
the efficacy of CAR T cells to treat patients with B-cell malignancies by targeting 
either the inactive tyrosine-protein kinase transmembrane receptor ROR1, the 
immunoglobulin kappa chain (Igκ), CD20 or CD22 (Jackson et al., 2016).  
The human cell surface CD22 antigen which is essential in B-lineage differentiation, 
has a B cell-restricted expression, including malignant B cells (Nitschke, 2009; 
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Tedder et al., 2005; Tu et al., 2011). CD22 is highly expressed in B-ALL ranging from 
50-100% expression (Shah et al., 2015). Its restricted expression profile and the 
clinical success of related therapies like Epratuzumab confirm CD22 as an excellent 
potential therapeutic target in B cell malignancies. A novel CD22 targeted CAR T cell 
therapy would therefore be an ideal treatment option. Derived from the clinically 
established murine IgG1 antibody RFB4 (Campana et al., 1985), the previously 
generated humanized and highly specific anti-CD22 scFv (Krauss et al., 2003b) is a 
well-suited antibody for the development of this new therapy.  
 
1.5 Aim of the study  
During the treatment of hematological malignancies with antigen specific CAR 
T cells, surviving target-negative tumor cell subpopulations are often emerging. 
Consequently, to improve the overall long term survival rate of relapsed and 
refractory leukemia and lymphoma patients, alternative CAR therapies targeting new 
antigens are needed. The goal of the present thesis is the generation of a CD22 
specific chimeric antigen receptor for the adoptive T cell therapy of CD22 positive 
leukemia and lymphoma.  
For this purpose, a highly stable humanized anti-CD22 scFv is used as antigen 
binding domain and cloned into a third generation CAR backbone comprising the 
signal transduction domains of CD3ζ, CD28 and 4-1BB. We first investigate CAR 
stability by determining if the stability of the scFv is maintained when expressed in a 
CAR format. The humanized anti-CD22 CAR is expected to be more stable than its 
murine counterpart which is analyzed in comparison. 
Mutations introduced in the human Fc spacer (ΔFc) and in the co-stimulatory CD28 
domain (ΔCD28) aim to reduce the on-target, off-tumor toxicity while enhancing 
tumor specific cell death induction in the presence of regulatory T cells. The novel 
parental, the ΔFc and ΔCD28 single mutated as well as the double mutated 
ΔFc-ΔCD28 CD22 CAR variants are characterized in vitro. Through lentiviral gene 
transfer, each CAR variant is transduced into T cells isolated from human blood and 
its CAR T cell activation is investigated in vitro. CD22 CAR T cell dependent target 
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affinity, cytokine release and lysis of antigen presenting tumor cells are assessed in 
depth for each variant. 
Within this project, a CD22 CAR lead candidate with the best profile regarding 
effectiveness, stability and safety is selected and will be further developed for a 
translation into the clinic. For following preclinical studies, the engraftment of 
leukemia tumor cells is examined in a preliminary in vivo study using a suitable 
mouse model.   
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2 Materials and methods 
2.1 Materials 
2.1.1 Laboratory equipment  
The laboratory equipment used in this thesis is listed in Table 1. 
Table 1: Laboratory equipment 
Instruments Description Supplier 
Balance 2200-2NM Kern & Sohn GmbH 
Centrifuges Heraeus Megafuge 16R 
Heraeus Megafuge 40R 
J2-MC 
Rotina 420R 
PCV-2400 
Micro 200R 
Thermo Scientific 
Thermo Scientific 
Beckman 
Hettich 
Grant-Bio 
Hettich 
CO2 incubator Nu-5500-E 
Heracell 150 
Nuaire 
Thermo Scientific 
Cryo conservation CoolCell LX BCS-405 Biocision 
Electroblotting system PowerPac Basic HC 
Trans-Blot Semy-Dry Transfer Cell 
Bio-Rad 
Bio-Rad 
Electrophoresis 
systems 
PowerPac Basic 
XCell SureLock Mini-Cell 
Bio-Rad 
Bio-Rad 
Flow cytometer FACS Canto Becton Dickinson 
FPLC system ÄKTA FPLC 
ÄKTA Pure 
GE Healthcare  
GE Healthcare 
Freezer MDF-U7 4V 
LGex 3410 Mediline 
Froster-720 
Sanyo Electrics 
Liebherr 
Kirsch 
Fridge LKexv 5400 Mediline 
LKexv 1800 Mediline 
Liebherr 
Liebherr 
Gel visualization Quantum ST4 Vilber Lourmat 
Heating block MRK-13 HLC 
Imaging Photon Imager Biospace Lab 
Microplate reader Epoch BioTek 
Microscope CKX31 Olympus 
pH-Meter PB-11 Sartorius 
Photometer NanoDrop ND-1000 
Epoch 
Thermo Scientific 
BioTek 
Pipette controllers Pipetus  
PIPETMAN classic 
PIPETMANN neo 
Hirschmann 
Gilson 
Gilson 
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PIPETGIRL Integra 
Rotating mixer RM5-30V Ingenieurbüro CAT 
Separator QuadroMACS Separator Miltenyi Biotech 
Shaker Innova44 
 
Multitron Pro 
New Brunswick 
scientific 
Infors HT 
Sterile benches Safe 2020 
HERAsafe KSP 
Thermo Scientific 
Thermo Scientific 
Thermal cycler T3000 Biometra 
Vacuum pump LC16 
N816.3KN.18 
ATMOS 
KMF Neuberger 
Vortex MS3 digital 
Vortexgene 2 G560E 
IKA 
Scientific Industries 
Water bath GFL-1003 GFL 
 
2.1.2 Disposables 
The disposables used in the present thesis are listed in Table 2. 
Table 2: Disposables 
Description Supplier 
Bottle top vacuum filter Nalgene 
Canula Becton Dickinson 
Cell culture flasks Greiner Bio-One 
Cell culture plates Greiner Bio-One 
Centricon Plus-70 Merk Millipore 
Conical tubes (15 ml, 50ml) Greiner Bio-One 
Costar assay plate, 96 well, half area Corning 
Cryogenic storage vials (2ml) Greiner Bio-One 
Dialysis membranes ZelluTrans Carl Roth 
Dispenser tips Greiner Bio-One; Corning; Biozym 
FACS tubes Becton Dickinson 
Gloves (latex-free) Sempermed 
MACS Separation column 25 LS column Miltenyi Biotech 
Micro tubes (1.5 ml, 2ml) Eppendorf 
Nitrocellulose membrane Neo-Lab 
Reagent reservoir Corning 
Serological pipets (5ml, 10ml, 25 ml, 50ml) Corning 
Sterile filter Millex-GS Merk Millipore 
Syringes (1ml, 2ml, 5ml, 10ml, 60ml) Becton Dickinson 
Tissue culture dish with 20 mm grid Corning 
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2.1.3 Chromatography columns 
Chromatography columns used on the FPLC-system are listed in Table 3. 
Table 3: Chromatography columns 
Column Supplier 
HisTrap FF (5 mL) GE Healthcare (17-5255-01) 
HiLoad 16/60 Superdex 75 prep grade GE Healthcare (17-1068-01) 
Superdex 200 10/300 GL GE Healthcare (17-5175-01) 
 
2.1.4 Standard kits 
Table 4 gives an overview of the used standard kits. 
Table 4: Standard kits 
Description Supplier 
Cell proliferation Kit II (XTT) Roche (11 465 015 001) 
EndoFree Plasmid Giga Kit QIAGEN (12391) 
EndoFree Plasmid Mega Kit  QIAGEN (12381) 
FITC Annexin V apoptosis Detection Kit Becton Dickinson (556547) 
Human IFNγ ELISA Set Becton Dickinson (555142) 
Human IL-2 ELISA KIT Set Becton Dickinson (555190) 
NucleoBond Xtra Maxi Plus Macherel-Nagel (740416.50) 
Pan T Cell Isolation Kit Miltenyi Biotech (130-096-535) 
QIAprep Spin Miniprep Kit QIAGEN (27106) 
QIAquick  Gel Extraction Kit QIAGEN (28706) 
QIAquick PCR Purification Kit QIAGEN (28106) 
 
2.1.5 Chemicals and reagents 
Chemicals and reagents used in this thesis are listed in Table 5. 
Table 5: Chemicals and reagents 
Product Supplier 
Agar BD Biosciences (214010) 
Agarose Invitrogen (16500-500) 
Carbenicillin Carl Roth (6344.2) 
Coomassie Brilliant Blue R-250 (C.I. 42660) Carl Roth (3862.1) 
Disodium hydrogen phosphate (Na2HPO4) Carl Roth (P030.2) 
DMEM Gibco (31053-028) 
DMEM + GlutaMAX Gibco (61965-026) 
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DMSO  Serva (20385.01) 
DNA gel loading buffer New England Biolabs (B7021S) 
DNA ladder  
(100 bp and 1000 bp) 
New England Biolabs  
(N3231S and N3232L) 
DTT Carl Roth (6908.3) 
Dulbecco´s PBS; no Calcium; no Magnesium Gibco (14190-094) 
EDTA Sigma (E5134-250G) 
Ethanol extra pure Carl Roth (9065.1) 
Ethidium bromide Carl Roth (2281.1) 
FBS PAN Biotech (P40-47500) 
Ficoll Plaque PLUS GE Healthcare (17-1440-03) 
FreeStyle F17, without L-Glutamine Thermo Scientific (A1383501) 
Geneticindisulfate (G418) solution (50mg/ml) Carl Roth (0239.3) 
Glycerol  AppliChem (A3739,0500) 
Hydrochloric acid  Carl Roth (4265.1) 
IL-2 (PROLEUKIN® S 18 Mio. IE) Novartis (02238131) 
Imidazol Carl Roth (X998.4) 
Isofluran Baxter 
Isopropanol Carl Roth (9866.2) 
Kanamycin  Carl Roth T832.1 
Kolliphor P188 Sigma-Aldrich (15759) 
L-glutamine 200 mM  Thermo Scientific (25030081)  
Luciferin-EF Promega (E655B) 
Methanol Carl Roth (8388.2) 
Milk Powder Carl Roth (T154.2) 
Opti-MEM reduced serum medium Thermo Scientific (31985062)  
Penicillin-Streptomycin (10000 U/ml und 10mg/ml) Sigma-Aldrich (P0781) 
Pierce ECL Western Blotting Substrate Thermo Scientific (32106) 
Polybrene Hexadimethrine bromide Sigma (107689) 
Polyethylenimine  Polysciences (23966) 
Potassium chloride  Carl Roth (6781.1) 
Potassium dihydrogen phosphate  Carl Roth (P018.1) 
Rainbow Fluorescent Particle 3.0 - 3.4 µm Becton Dickinson (556291) 
RPMI-1640 + GlutaMAX Gibco (61870-010) 
Sodium bicarbonate Carl Roth (A135.1) 
Sodium carbonate Carl Roth (6885.2) 
Sodium chloride Carl Roth (3957.1) 
Sodium dihydrogen phosphate Carl Roth (K300.3) 
Sodium dodecyl sulfate Carl Roth (2326.1) 
Spectra multicolor Broad Range Protein Ladder Thermo Scientific (26634) 
Sulfuric acid  In house 
TMB Substrate reagent Set Becton Dickinson (555 214) 
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TN1, tryptone 1 Organotechnie (19553) 
Tris Carl Roth (4855.2) 
Trypsin/EDTA PAN Biotech (P10-0231 SP) 
Tryptan blue  Sigma (T8154) 
Trypton/Pepton ex casein Carl Roth (8952.3) 
Tween 20  Gerbu (2001.0500) 
X-Vivo 20 Lonza (BE04-448Q) 
Yeast Extract Carl Roth (2363.3) 
 
2.1.6 Buffer and solutions 
Buffer and solutions were prepared as shown in Table 6.  
If nothing is additionally mentioned, components were diluted in distilled water 
(dH2O) and pH adjusted with sodium hydroxide or hydrochloric acid. 
Table 6: Buffer and solutions 
Description Composition 
PBS PBS, 10x (10%; v/v) 
PBS 10X 1,4 M NaCl 
27 mM KCl 
101 mM Na2HPO4 
18 mM KH2PO4  
PBS-T 0,5 ml/l Tween 20 
in PBS 
MPBS 20 g/l milk powder 
in PBS 
FACS buffer 2 mM EDTA 
1% FBS 
in PBS 
IMAC binding buffer (pH 7,4) 20 mM NaH2PO4 
500 mM NaCl 
10 mM Imidazol 
IMAC elution buffer (pH 7,4) 20 mM NaH2PO4 
500 mM NaCl 
500 mM Imidazol 
Western Blot Transfer buffer  48 mM Tris 
39 mM Glycin 
1,3 mM SDS 
20% (v/v) methanol 
adjusted to pH 9.0, filter sterilized 
Coomassie solution 70 mg/l Coomassie Brilliant Blue G-250 
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35 mM HCl  
DTT solution (10X) 2,5 M DTT 
ELISA Coating Buffer  7,13 g/l NaHCO3 
1,59 g/l Na2CO3 
adjusted to pH 9.5 
ELISA Assay Diluent 10% FBS 
in PBS 
ELISA Wash Buffer 0,05% Tween-20 
in PBS 
2N H2SO4  13,89 ml H2SO4 
236,11 ml H2O 
TAE Buffer 242 g/l Tris  
100 ml/l EDTA 
57,1 ml/l glacial acetic acid 
Freezing medium 10% DMSO (v/v) 
in FBS 
 
2.1.7 Primers 
Oligonucleotides used for sequencing (method 2.2.10) or for site-directed 
mutagenesis (method 2.2.7) are summarized in Table 7.  
All primers were purchased from Invitrogen (Life Technologies). 
Table 7: Primers for sequencing and mutagenesis 
Name Sequence (5‘-3´) 
Sequencing primers  
pENTR sense CATAAACTGCCAGGCATCAAACTAAG 
pENTR AS GATTTTGAGACACGGGCCAGA 
PCR2 TTAGCTCACTCATTAGG 
Primer for PCR  
RFB4_1 TCGGAAGTGCAGCTGGTGGAG 
RFB4_2 TATAGGATCCTTTGATTTCCAGCTT 
hCD22_1 GCCACCATGGAAAGGCACTGGATCTTTCTC 
hCD22_2 TAGCGGCCGCACGTTTGATTTCCAGTTTGG 
Mutagenesis primers  
hIgG1_CH2-Fw AAGGTCTCCAACAAAGCC 
hIgG1_CH2-Rev TTGTTGGAGACCTTGCAC 
CD28_Lck-Fw CCCACCCGCAAGCATTACCAGGCCTA 
TGCCGCCGCACGCGACTTCGCAGCCTAT 
CD28_Lck-Rev ATAGGCTGCGAAGTCGCGTGCGGCG 
GCATAGGCCTGGTAATGCTTGCGGGTGGG 
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hCD22_LY-Fw CAATTATTTAAACTGGTACCAACAGAAACCAGGGAAAG 
hCD22_LY- Rev CTTTCCCTGGTTTCTGTTGGTACCAGTTTAAATAATTG 
 
2.1.8 Plasmids  
In Table 8, the used vectors are briefly described. The corresponding vector maps 
are illustrated in the appendix. 
Table 8: Plasmids 
Vector Description  
pENTR1a Entry vector for LR reaction of Gateway cloning 
pRRL Lentiviral vector used for transient expression of 
lentivirus in mammalian cells 
Lentiviral helper plasmid #1 Helper plasmid for lentivirus production 
Lentiviral helper plasmid #2 Helper plasmid for lentivirus production  
pEUC6B Subcloning vector for scFv cloning 
pEE12.4 Used for transient expression of scFv antibodies by 
mammalian cells 
 
2.1.9 Antibodies 
Commercially purchased antibodies and antibodies conjugates are described in 
Table 9. 
Table 9: Antibodies and antibody conjugates 
Name Description 
R-Phycoerythrin conjugated AffiniPure 
F(ab´)2 fragment goat anti-human IgG 
(Jackson ImmunoResearch, 109-116-
098) 
Polyclonal F(ab’)2 fragment from goat 
against human IgG (Fc specific), linked to 
R-Phycoerythrin (PE) 
APC Mouse Anti-Human CD3 
(Becton Dickinson, 555335) 
Monoclonal IgG from mouse against 
human CD3, linked to Allophycocyanin 
(APC) 
Pacific Blue Mouse Anti-Human CD3 
 (Becton Dickinson, 558117) 
Monoclonal IgG from mouse against 
human CD3, linked to Pacific Blue 
PE-Cy 7 Mouse Anti-Human CD19 
 (Becton Dickinson, 557835) 
Monoclonal IgG from mouse against 
human CD19, linked to a dye combining 
Phycoerythrin and cyanine (PE-Cy 7) 
PE-Cy 7 Mouse Anti-Human CD14 
(Becton Dickinson, 557742) 
Monoclonal IgG from mouse against 
human CD14, linked to PE-Cy 7 
OKT-3 Monoclonal IgG from mouse against 
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(in house) human CD3 
Streptavidin Alexa Fluor 488 
(Thermo Scientific, S11223) 
Streptavidin covalently bound to Alexa 
Fluor 488 dye 
HRP Mouse Anti-His  
(Santa Cruz, S8036) 
Monoclonal IgG from mouse against 
histidine tag 
Mouse anti c-myc antibody  
(Roche, 11667149001) 
Monoclonal IgG from mouse against 
c-myc tag (clone 9E10) 
FITC Goat Anti-Mouse IgG 
(Jackson ImmunoResearch, 115-095-
008)  
Polyclonal IgG from goat against murine 
IgG (Fc-specific), linked to Fluorescein 
(FITC) 
 
2.1.10 Enzymes and proteins 
Enzymes and proteins used in this thesis are listed in Table 10. 
Table 10: Enzymes and proteins 
Enzymes / Proteins Supplier 
Alkaline Phosphatase from calf intestine New England Biolabs 
Pfu Plus DNA Polymerase Thermo Scientific 
T4 DNA Ligase Thermo Scientific 
Gateway LR Clonase TM II Invitrogen (11791-100) 
Restriction enzymes New England Biolabs 
Human Fc (hFc) protein In house 
Recombinant human CD22-hFc (hCD22-hFc) Prof. Nitschke, Erlangen University 
Biotin-Protein L Genscript  
 
2.1.11 Bacteria strain 
Amplification of DNA was performed with the bacterial strain Escherichia coli (E. coli) 
XL1-Blue (Table 11). 
Table 11: Bacteria strain 
Bacteria strain Supplier 
Escherichia coli XL1-Blue 
Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´pro AB lac1qZ∆M15 Tn10 
(Tetr)] 
Agilent; #200249 
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2.1.12 Bacteria culture media and supplements 
Bacterial culture media were prepared as shown in Table 12. 
Table 12: Bacterial culture media 
Description Composition 
LB high salt 10 g/l trypton, 5 g/l yeast extract, 10 g/l NaCl, in dH2O 
autoclaved 
LB agar 15 g agar in 1l LB 
Ampicillin stock solution 100 mg/ml ampicillin sodium salt, in dH2O, filter 
sterilized. For the selection of ampicillin resistant 
bacterial strain, the used concentration was 100 µg/ml. 
Kanamycin stock solution 100 mg/ml ampicillin sodium salt, in dH2O, filter 
sterilized. For the selection of ampicillin resistant 
bacterial strain, the used concentration was 100 µg/ml. 
 
2.1.13 Eukaryotic cell line and primary cells 
An overview of used cell lines is represented in Table 13. The cell line THP-1 was 
kindly provided by Prof. Dr. med Hinrich Abken, Universität Köln. The cell line 
HEK-293-E was licensed from the National Research Council, Biotechnological 
Research Institute, Montreal, Canada.  
Table 13: Human cell lines and primary cells 
Cell line Description; Supplier Culture medium 
HEK-293-E Human embryonic kidney 293 
adapted for suspension culture 
and optimized for high protein 
expression 
National Research Council 
FreeStyle F17 
HEK-293T Human embryonic kidney 293 
cell line stably expressing the 
SV40 large T antigen 
ATCC, CRL 3216 
DMEM 
Raji Burkitt´s lymphoma 
ATCC, CCL-86 
RPMI-1640 
Nalm-6 Acute lymphoblastic leukemia 
DSMZ, ACC-128 
RPMI-1640 
Luciferase transfected 
Nalm-6  
Acute lymphoblastic leukemia 
in house 
RPMI-1640 
Jurkat Acute T cell leukemia 
ATCC, TIB-152 
RPMI-1640 
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MCF-7 Adenocarcinoma 
ATCC, HTB-22 
DMEM 
THP-1 Acute monocytic leukemia 
Prof. Dr. med H. Abken 
Universität Köln 
RPMI-1640 
Human peripheral blood 
mononuclear cells 
(PBMC) 
Isolated from fresh blood or 
buffy coats (platelet and 
leucocyte fraction from blood 
donations) from healthy donors. 
Buffy coats were obtained from 
DRK Blutspendedienst 
Mannheim 
X-Vivo 20 
 
2.1.14 Cell culture media 
Cell culture media were prepared as described in Table 14. 
Table 14: Cell culture media 
Description Composition 
DMEM DMEM + Glutamax 
+ FBS (10%, v/v) 
+ Penicillin (100 U/ml) 
+ Streptomycin (100 µg/ml) 
DMEM w/o FBS DMEM 
+ Penicillin (100 U/ml) 
+ Streptomycin (100 µg/ml) 
RPMI-1640 RPMI-1640 + Glutamax 
+ FBS (10%, v/v) 
+ Penicillin (100 U/ml) 
+ Streptomycin (100 µg/ml) 
FreeStyle F17 FreeStyle F17 
+ Kolliphor P188 (10 ml/l) 
+ L-glutamine (20 ml/l) 
+ G418 (0,5 ml) 
X-Vivo 20 X-Vivo 20 
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2.1.15 Mice 
The mouse strain used for the preliminary in vivo assay is listed in Table 15. 
Table 15: Mice 
Mouse strain and description Supplier 
NOD.CB17-Prkdc^scid/NCrHsd 
six to eight weeks of age, female 
Envigo (17004F) 
 
2.1.16 Data treating software 
Overview of used software and their applications are listed in Table 16. 
Table 16: Software 
Software Description Supplier 
FACSDiva  Acquisition and analysis of flow 
cytometer data 
Becton Dickinson 
FACSSuite Acquisition and analysis of flow 
cytometer data 
Becton Dickinson 
Gen 5.2 Data processing of used plate reader BioTek 
Genious R6.1.6 Sequence evaluation and vector 
visualization 
Biomatters 
GraphPad Prism 5.0  Figure preparation; Statistical 
analysis 
GraphPad software 
Mendeley Reference manager Elsevier 
MS Office 2010 Data evaluation, text processing Microsoft 
ND-1000 V3.8 Protein concentration measurement Tecan 
Photoshop Elements 10 Image processing Adobe Systems 
Photovision + Image acquisition Biospace Lab 
Quantum ST4 Gel documentation Vilber Lourmat 
SilverFast 8 Image acquisition LaserSoft Imaging 
Unicorn 5.10 Flow cytometry analysis and 
evaluation 
GE Healthcare 
Unicorn 6.3 Flow cytometry analysis and 
evaluation 
GE Healthcare 
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2.2 Molecular based methods 
2.2.1 Restriction enzyme digestion 
Digestion of DNA with restriction enzymes was performed according to the 
manufacturer’s instructions (New England Biolabs). In a final volume of 20 µl, 
2  4 units of restriction enzyme per 1 µg of DNA as well as 1x buffer was used to 
carry out the digestion at 37 °C for 1 h.  
For a plasmid digestion, in order to prevent religation, 5 units of alkaline phosphatase 
calf-intestinal (CIP) was added to dephosphorylate the vector.  
 
2.2.2 Gel electrophoresis and gel extraction 
To verify their size (method 2.2.1), digested DNA fragments were analyzed by 
agarose gel electrophoresis. A 0.8 - 2% agarose gel was prepared by first boiling the 
desired amount of agarose in 1x TAE buffer and then mixing this solution with 
0.5 µg/ml of ethidium bromide, a DNA intercalating agent. Samples blended with 
5x gel loading dye were electrophoretically separated together with a size standard in 
1x TAE buffer at 75 volts. 
DNA band with the correct size was extracted from the agarose gel with a scalpel 
and purified using the Qiaquick Gel Extraction Kit according to the manufacturer’s 
instructions (QIAGEN). 
 
2.2.3 DNA purification  
Purification of specific DNA fragments having the correct size was performed using 
the Qiaquick PCR purification Kit according the manufacturer’s instructions 
(QIAGEN). 
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2.2.4 Ligation 
In a final volume of 20 µl, 50 ng digested plasmid was mixed together with a 3x molar 
excess of digested DNA insert, 1 unit of T4 DNA ligase and 2 µl of 10x ligase buffer. 
Ligation reaction occurred for one hour at room temperature and 2 µl of the 
preparation was further transformed in E.coli XL1-Blue bacteria (method 2.3.1). 
 
2.2.5 Preparation of plasmid DNA 
Small and high amount of plasmid DNA were respectively prepared with the QIAprep 
Spin Miniprep Kit (QIAGEN) and NucleoBond Xtra Maxi Plus (Macherey-Nagel).  
Plasmid DNA for lentivirus production (method 2.5.1) was obtained with either the 
EndoFree Plasmid Mega Kit or EndoFree Plasmid Giga Kit (QIAGEN).  
All the preparations were performed according to the manufacturer’s instruction. 
 
2.2.6 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was applied to amplify DNA and to introduce 
new gene sequences as well as restriction sites. For this purpose, the KAPAHifi PCR 
Kit was used according the manufacturer’s instructions. Mixture of a typical PCR 
reaction is shown in Table 17. 
Table 17: PCR reaction 
Component Volume (µl) Final amount/concentration 
DNA 1-5 5-20 ng 
5x KAPAHifi buffer 5 1x 
dNTP mix (10 mM) 0.75 300 µM each 
5‘ primer (25 µM) 0.5 500 nM 
3‘ primer (25 µM) 0.5 500 nM 
KAPAHifi Polymerase (1 U/µl) 0.5 0.02 U/µl 
H2O ad 25 - 
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Reaction was performed in the thermal cycler T3000 (Biometra) according to the 
condition presented in Table 18. The appropriate melting temperature of each primer 
was estimated with the following formula:  
Tm = [4x(C+G) + 2x(A+T)] - 4 °C 
Table 18: PCR conditions 
Step Temperature (°C) Time Cycles 
Initial denaturation 98 5 min 1X 
Denaturation 98 30 sec  
Annealing Tm 30 sec 18-35X 
Elongation 72 30 sec  
Finale elongation 72 7 min 1X 
Cooling 4 ∞ 1X 
 
2.2.7 Site directed mutagenesis  
Site directed mutagenesis is a method to introduce specific mutations in a double 
strand plasmid DNA. The mixture of a typically site directed mutagenesis performed 
with the Pfu DNA polymerase is presented in Table 19. 
Table 19: Site directed mutagenesis preparation 
Component Volume (µl) Final amount/concentration 
Plasmid DNA 1 100 ng 
10x Pfu buffer 5 1x 
dNTP mix (10 mM) 1.25 0.2 mM each 
Mutagenic primer 1 (100 ng/µl) 1.25 125 ng 
Mutagenic primer 2 (100 ng/µl) 1.25 125 ng 
Pfu Plus Polymerase (5 U/µl) 0.5 2.5 U 
H2O ad 50 - 
 
Reaction was performed in the thermal cycler T3000 (Biometra) according to the 
following conditions (Table 20): 
 
 
31 
 
Table 20: Site directed mutagenesis conditions 
Step Temperature (°C) Time Cycles 
Initial denaturation 95 5 min 1X 
Denaturation 95 1 min  
Annealing 68 30 sec 18X 
Elongation 68 1 min/1 Kb  
Finale elongation 68 7 min 1X 
Cooling 15 ∞ 1X 
 
To finalize the site directed mutagenesis, the preparation was digested with DpnI for 
2 h at 37 °C in order to cut the methylated non mutated strand. Transformation in 
competent E.coli XL1-Blue bacteria was performed with 10 µl of the DNA mixture. 
 
2.2.8 Gateway cloning 
For the gateway reaction, 200 ng DNA of the entry clone containing the CAR gene of 
interest flanked by attL1 and attL2 sequences was mixed with 200 ng DNA of the 
destination vector (Figure 6). After adding 1 µl LR clonase enzyme mix to the 
preparation an incubation of 1 h at room temperature allows the enzyme to first 
excise the CAR gene from the entry clone and then to integrate it into the destination 
vector, resulting in the new formed expression clone containing the CAR gene. To 
stop the reaction, 0.5 µl proteinase K (2 mg/ml) was added and the preparation 
incubated for 10 min at 37 °C. Transformation in competent E.coli XL1-Blue bacteria 
and selection of carbenicillin resistant expression clones was performed with 2 µl of 
the DNA mixture. When using the BP clonase, the reaction can be performed in the 
opposite way. 
 
Figure 6: Schematic representation of the gateway cloning 
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2.2.9 Concentration measurement of DNA 
Concentration of H2O diluted double strand DNA was determined on a 
spectrophotometer. The absorbance (Abs) of the samples was measured at a 
wavelength of 260 nm and 280 nm and purity of the preparation was given by the 
ratio Abs 260 nm / Abs 280 nm. 
 
2.2.10 Sequencing 
Sequencing of plasmid DNA was carried out by the company GATC using the 
customized sequencing primers pENTR sense, pENTR AS and PCR2. Their 
sequences are shown in Table 7 and their binding positions are represented on the 
vector maps in appendix.  
 
2.3 Bacteria and cell based methods 
2.3.1 Transformation of bacteria 
Chemically-competent XL1-Blue bacteria were slowly thawed on ice and 100 µl was 
added to the transforming DNA (10 µl of ligation or 2 µl of gateway reaction) carrying 
carbenicillin or kanamycin resistance already present in a cold Eppendorf tube. The 
bacteria/DNA suspension was first incubated on ice for 30 min, then at 42 °C for 
90 sec and finally again on ice for 5 min. After adding 1 ml of LB medium, the mixture 
was shaken at 200 rpm and 37 ºC for 30 - 60 min. Bacteria were spread on LB agar 
plates containing carbenicillin (100 µg/ml) or kanamycin (50 μg/ml). The plates were 
incubated over night at 37 ºC and a single colony was picked from the plate the next 
day. 
 
2.3.2 Cultivation of cells  
The suspension cell line HEK-293-E was cultivated in a humidified shaker under 
constant conditions (120 rpm, 37 °C, 5% CO2) in FreeStyle F17 medium with 0.1% 
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Kolliphor P188, 4 mM Glutamin and 25 μg/ml G418. Cells were splitted two to three 
times per week never allowing the maintained cells to exceed 2x106 cells/ml. 
Adherent cell lines HEK-293T and MCF-7 were cultivated in DMEM with GlutaMAX 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml 
streptomycin in a humidified incubator with 5% CO2 at 37 °C. Suspension cell lines 
Nalm-6, Raji, Jurkat and THP-1 were cultivated under the same conditions in 
RPMI-1640 with GlutaMAX supplemented with 10% FBS, 100 U/ml penicillin and 
100 mg/ml streptomycin whereas luciferase transfected Nalm-6 cells were cultivated 
in the same medium with additionally G418 (0.2 mg/ml). All these cell lines were 
maintained in 20 ml adapted culture medium, in T75 culture flasks and splitted two 
times per week (final cell density of 2x105 cells/ml). Adherent cell lines were washed 
with 10 ml PBS and detached from a T75 flask by first adding 2 ml of a trypsin-EDTA 
solution and then incubating the suspension for 5 - 10 min at 37 °C. Cells were finally 
resuspended with 8 ml fresh medium. Suspension cells were directly diluted from the 
culture flask. 
 
2.3.3 Freezing and thawing cells 
For freezing, cell lines were centrifuge at 200 g for 10 min (adherent cells being 
previously detached from the bottom of a T75 flask as described in the method 
2.3.2). After one washing step with adapted cell culture medium, the obtained cell 
pellet was resuspended in FBS with 10% (v/v) DMSO. This cell suspension, with a 
concentration of 0.5 - 1x107 cells/ml was transferred in a cryovial and frozen to -80 °C 
at 1 °C/min in a cryo freezing container. Storage takes place in liquid nitrogen. 
Cryo-conserved cell lines were rapidly thawed in a water bath at 37 °C and 
transferred in a 50 ml Falcon tube. Pre-warmed culture medium was then added drop 
wise to the cell suspension before transferring it into a T25 flask for cultivation. 
Depending on growth, expansion in a T75 flask occurs two to three days later. 
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2.3.4 Transient production of scFv in mammalian cells 
Murine anti-CD22 scFv RFB4 was transiently expressed in HEK-293-E cells and 
secreted in the cell culture supernatant. Two days before transfection, HEK-293-E 
cells were seeded with a cell density of 0.5x106 cells/ml in F17 medium containing 
0.1% Kolliphor P188, 4 mM Glutamin as well as 25 μg/ml G418 and incubated in a 
humidified shaker under constant conditions (120 rpm, 37 °C, 5% CO2). Transfection 
reagent polyethylenimine (2 µg/ml final concentration) and endotoxin free plasmid 
DNA (1 µg/ml final concentration) were separately prepared in 1/20 of the final 
culture volume in F17 medium without G418. After mixing both preparations together, 
the solution was incubated at room temperature during a few minutes and added to 
HEK-293-E cells having a cell density of 1.7 - 2x106 cells/ml. One day later, the cell 
suspension was supplemented with 0.5% (w/v) trypton N1. After 5 days, cells were 
centrifuged at 200 g for 20 min at 4 °C. Obtained supernatant was further clarified by 
a second centrifugation step (200 g, 20 min at 4 °C) and purified using an 
immobilized metal ion chromatography (method 2.4.1) and a size exclusion 
chromatography (method 2.4.2). 
 
2.3.5 Determination of scFv stability  
To determine the scFv stability, mammalian produced (method 2.3.4) antibody 
fragments (12 µg/ml) were incubated in 90% human serum or PBS over 7 days at 
37 °C and 5% CO2. At different time points, a sample was taken out and stored at      
-20 °C before analyzing its binding to antigen expressing cells. 
To determine the binding of the antibody fragments, 5x105 Raji cells were incubated 
with 100 µl of each stored scFv sample at 4 °C for 60 min. After several washing step 
with Fluorescence-Activated Cell Sorting (FACS) buffer, cells were resuspended with 
100 µl of mouse anti c-myc antibody (5 μg/ml; Roche) and incubated at 4 °C for 
45 min. To detect bound antibody fragments, cells were washed again and incubated 
with a FITC conjugated goat anti-mouse antibody (7.5 μg/ml; Jackson 
ImmunoResearch) at 4 °C for 30 min in the dark. Fluorescence of marked cells was 
measured with the FACSSuite software. For each sample, the fluorescence signal of 
the negative control (Raji cells incubated with the detection antibodies) was 
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subtracted from the calculated mean of fluorescence. All the values were 
standardized to the mean of fluorescence obtained for the time point 0 h 
corresponding to 100% scFv binding to Raji cells. 
 
2.3.6 Measurement of the expressing CAR T cells by FACS  
To determine the lentivirus titer and the transduction rate, the percentage of T cells 
expressing the CAR construct on their surface was determined by flow cytometry 
(FACS).  
After removing the medium from the titration plate (method 2.5.2), cells were 
resuspended in 1 ml PBS and transferred into FACS tubes whereas 200 - 500 µl of 
the transduced cell suspension (method 2.5.3) was directly transferred into FACS 
tubes. Addition of 2 ml FACS buffer and centrifugation at 1400 rpm for 4 min allows 
washing the cells. After removing the supernatant, the cell pellet was resuspended in 
2 ml FACS buffer for a second washing step. Once the supernatant discarded, cells 
were resuspended in 100 µl FACS buffer. Specific detection antibodies were added 
to the cells and the cell suspension further incubated for 30 min at 4 °C in the dark. In 
order to remove the antibody excess, cells in the FACS tubes were washed two times 
with FACS buffer as previously mentioned. After a final resuspension in 400 µl PBS, 
the expression of CAR T cells was measured by using the FACSCanto flow 
cytometer.  
 
2.3.7 Apoptosis assay  
The tumor cell lysis was determined with an Annexin V Apoptosis detection Kit 
(Becton Dickinson). In case of apoptosis, phosphatidylserine normally located along 
the cytoplasmic side of the membrane is translocated to the extracellular membrane 
and therefore detectable by the highly fluorescently conjugated protein annexin V. 
The vital stain propidium iodide (PI) is unable to enter living cells during early 
apoptosis but can bind the DNA during late apoptosis.  
To evaluate the tumor cell lysis induced by CAR T cells, these effector cells were 
co-incubated with target positive and negative tumor cells. The fraction of positively 
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expressing CAR T cells varied from 0% to 60% between the CAR constructs and 
between the donors (method 2.3.6). Therefore, the amounts of transduced CAR 
T cells were adjusted to incubate the same quantity of positively expressing CAR 
T cells. 
In a well of a 48 well plate, 1x105 expressing CAR T cells (previously washed two 
times with PBS) were incubated with 1x105 target positive or negative tumor cells in 
1 ml RPMI-1640 with GlutaMAX supplemented with 10% fetal bovine serum, 
100 U/ml penicillin and 100 mg/ml streptomycin for 48 h at 37 °C and 5% CO2. As 
control, effector cells and tumor cells only were incubated in the same conditions. 
Every reaction was performed in triplicates. 
After two days, plates were centrifuged at 1400 rpm for 4 min. The supernatant was 
removed and transferred in a new 48 well plate to determine the secreted amount of 
IFNγ with an IFNγ ELISA (method 2.4.8). The remaining cells were resuspended, 
transferred in FACS tubes and washed two times with 2 ml FACS buffer 
(centrifugation at 1400 rpm for 4 min). After discarding the supernatant of each tube, 
specific detection antibodies (Becton Dickinson) were incubated with the remaining 
100 µl cell suspension. CD3+ T cells as well as Jurkat cells were detected with Pacific 
Blue conjugated mouse anti-human CD3 antibody (0.2 mg/ml; Becton Dickinson), 
Nalm-6 and Raji cells with PE-Cy7 mouse anti-human CD19 antibody (dilution 
1:40; Becton Dickinson) whereas the THP-1 cells were identified with PE-Cy7 mouse 
anti-human CD14 antibody (dilution 1:20; Becton Dickinson). After 30 min at 4 °C, 
cells were washed twice with FACS buffer as previously explained whereby the 
supernatant was completely removed after the last washing step. Cell pellets were 
resuspended with annexin V binding buffer (1x), centrifuged at 1400 rpm for 4 min 
and the supernatant again discarded. To the 100 µl remaining cell suspension, 
annexin V (dilution 1:20) and PI (dilution 1:20) were added and the solution vortex 
before an incubation of 15 min at room temperature in the dark. Annexin binding 
buffer (1x) and 10 µl Rainbow beads (10x106 particles/ml) were supplemented to the 
FACS tubes before analyzing the percentage of living tumor cells with the flow 
cytometer FACS Canto II (Becton Dickinson) and the FACSDiva software (Becton 
Dickinson). 
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2.3.8 Isolation of human T cells  
Isolation of human T lymphocytes was performed in two distinct steps. Peripheral 
blood mononuclear cells (PBMCs) were first isolated from the blood of a healthy 
donor by Ficoll density gradient centrifugation. In a second step, isolation of human 
CD3+ T cells by depletion of magnetically labeled cells was done using the Pan T cell 
isolation Kit (Miltenyi Biotech).  
A buffy coat (25 ml) obtained from the Blutbank Heidelberg was divided into 6, diluted 
with PBS to a finale volume of 35 ml, slowly layered over 15 ml of Ficoll-Plaque and 
centrifuge at 2200 rpm for 20 min whereby the brake was switched off. After the 
centrifugation, upper phases corresponding to the plasma were discarded. The 
interphases containing the mononuclear cells were slowly removed and transferred in 
new falcon tubes. After diluting the interphases with PBS to a final volume of 50 ml, 
they were centrifuged at 1800 rpm for 10 min whereby the brake was switched on. 
The supernatants were then removed and each cell pellet was resuspended 
separately in 50 ml fresh PBS before a new centrifugation step at 1400 rpm for 
10 min. After removing the supernatants, the six cell pellets were resuspended 
together in 50 ml fresh PBS in order to pursue the isolation of human T lymphocytes. 
The Pan T cell isolation Kit was used according to the manufacturer’s instruction. The 
method consists of a negative selection of CD3+ T cells. Cell surface antigens of 
non-targeted cells are recognized by using a cocktail of biotin conjugated antibodies. 
The binding of anti-biotin MicroBeads to these antibodies allows to magnetically label 
the non-targeted cells which are retained on the magnetic separation column 
whereas the fraction of CD3+ cells passed through the magnetic field. 
 
2.3.9 Activation of human isolated T cells 
Isolated CD3+ T cells were cultivated in X-Vivo 20 medium with IL-2 (300 U/ml) and 
the agonistic anti-CD3 antibody OKT-3 (100 ng/ml). After 48 to 72 h, almost all the 
cells were in an active division phase which is a prerequisite for lentiviral gene 
transfer. 
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2.3.10 XTT assay 
The potency of CAR T cells towards tumor cell killing was determined with the cell 
proliferation Kit II (Roche).  
To evaluate the tumor cell lysis induced by CAR T cells, these effector cells were 
co-incubated with target positive tumor cells. The fraction of positively expressing 
CAR T cells varied from 0% to 60% between the CAR constructs and between the 
donors (method 2.3.6). Therefore, the amounts of transduced CAR T cells were 
adjusted to incubate the same quantity of positively expressing CAR T cells. 
In a well of a 96 well plate, 5x104 expressing CAR T cells (previously washed two 
times with PBS) were incubated with 5x104 target positive tumor cells in 200 µl 
RPMI-1640 with GlutaMAX supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin and 100 mg/ml streptomycin for 24 h at 37 °C and 5% CO2. As control, 
effector cells and tumor cells only were incubated in the same conditions. Every 
reaction was performed in triplicates. 
After one day, the plate was centrifuged at 1400 rpm for 4 min. The supernatant 
(150 µl) was removed and transferred in a new 96 well plate to determine the 
secreted amount of IFNγ with an IFNγ ELISA (method 2.4.8). The remaining cell 
suspension (50 µl) was mixed with 100 µl XTT labeling mixture and incubated for one 
hour in a humidified atmosphere. The mix was then blended again and the 
absorbance measured using a TECAN reader at 450 nm. To calculate the specific 
cytotoxicity, the difference between the means with and without the tumor cells was 
calculated, normalized to the mean of the medium alone (used as control). 
 
2.4 Protein based methods 
2.4.1 IMAC 
Purification of the produced murine anti-CD22 scFv was performed with an 
immobilized metal ion chromatography (IMAC) on a FPLC system. The supernatant, 
containing the protein was first dialyzed over night against IMAC binding buffer at 
4 °C (method 2.4.4). The next day, dialyzed solution was filtered using a 22 µm filter 
and loaded on a HIS Trap FF column with a flow rate of 1 ml/min. The bound scFv 
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fragments were eluted from the column with a linear increasing concentration of 
imidazol obtained by mixing the IMAC binding buffer (imidazol concentration of 
10 mM) with IMAC elution buffer (imidazole concentration of 500 mM). The eluted 
protein fractions were separated by SDS-PAGE (method 2.4.5) and purity of the 
recombinant protein was subsequently analyzed by Coomassie blue staining (method 
2.4.6) and western blot (method 2.4.7). Further purification of the murine scFv was 
performed by size exclusion chromatography. 
 
2.4.2 Preparative size exclusion chromatography 
Size exclusion chromatography was performed on a FPLC-system using the HiLoad 
16/60 Superdex 75 column. To obtain a precise separation on the column, the IMAC 
purified protein was first concentrated with centrifugal filter units and then injected 
into a 5 ml loop. The separation was performed at a flow rate of 0.3 ml/min in PBS. 
Eluted protein fractions were then further analyzed by Coomassie blue staining 
(method 2.4.6) and western blot (method 2.4.7) after SDS-PAGE (method 2.4.5). The 
purified monomeric protein fractions without aggregates and unspecific proteins were 
pooled, concentrated if needed, sterile filtered and finally stored at 4 °C. 
 
2.4.3 Analytical size exclusion chromatography 
The oligomeric state of purified antibody fragments was analytically assessed on a 
FPLC-system with the Superdex 200 10/300 GL column that was previously 
calibrated with protein standards of known molecular size. 10 µg of protein were 
loaded on a 25 µl loop and separated at a flow rate of 0.25 ml/min in PBS. 
 
2.4.4 Dialysis and protein concentration 
For the dialysis and concentration of recombinant proteins, membranes with define 
sizes were utilized. In order to obtain complete protein retention, the exclusion size of 
the used membranes was at least three times bigger than the molecular size of the 
protein. 
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Buffer exchanges of protein solutions were performed by dialysis. For this purpose, 
the dialysis membrane was first rehydrated by incubating it into the new buffer. After 
loading the membrane with the protein solution, the dialysis occurred in the new 
buffer with an excess volume of a 100 times the protein solution volume, overnight at 
4 °C under constant rotation. 
Concentration of the purified protein solution was performed with centrifugal filter 
units. The solution was therefore centrifuged at 4000 g, 4 °C until reaching the 
desired concentration. 
 
2.4.5 SDS-PAGE 
According to their molecular weight, the protein samples were separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). An SDS-PAGE gel 
consisting of a staking gel (5% acrylamide) and a separating gel (12% acrylamide) 
was poured. Protein samples were mixed with 5 µl of 4x reducing loading dye and 
5 µl of a 1 M DTT solution, then denatured at 70 °C for 10 min and finally transferred 
in the corresponding well. The separation via gel electrophoresis was then performed 
at 185 volts for 45 min. 
 
2.4.6 Coomassie blue staining 
For the detection of protein bands with Coomassie blue, electrophoretically separated 
SDS-PAGE gels were washed several times with dH2O and then stained in a 
Coomassie blue solution for one hour at room temperature. Distaining was performed 
with several washing step using dH2O until the protein bands were clearly visible. 
 
2.4.7 Western Blot 
The SDS-PAGE gel and a nitrocellulose membrane were separately equilibrated for 
10 min with the western-blot transfer buffer. The transfer of the protein bands from 
the gel to the nitrocellulose membrane occurred in a semi dry blotting system at 
25 volts for 30 min. To detect these recombinant proteins, the membrane was first 
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blocked for one hour in PBS-T containing 2% (w/v) milk powder. The immunostaining 
occurred through incubation with HRP conjugated anti-his antibody (2 µg/ml; Santa 
Cruz) diluted in PBS with 2% (w/v) milk powder. Unspecific antibody was then 
removed by washing two times with PBS-T and three times with PBS. Specific 
antibody binding was finally detected after incubation in Pierce ECL Western Blotting 
Substrate by chemiluminiscence. 
 
2.4.8 IFNγ and IL-2 ELISA 
The fraction of positively expressing CAR T cells varied from 0% to 60% between the 
CAR constructs and among the donors (method 2.3.6). Therefore, the amounts of 
transduced CAR T cells were adjusted to incubate the same quantity of expressing 
CAR T cells. 
A 1:2 serial dilution of CAR T cells (previously washed two times with PBS) starting at 
3x104 cells was performed and the cells further co-incubated with 3x104 tumor cells 
over 48 h (at 37 °C and 5% CO2) in 200 µl RPMI-1640 with GlutaMAX supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. In 
some experiments, instead of using tumor cells, hCD22-hFc and hFc antigens 
(3 µg/ml) were coated overnight on a 96 well plate at 4 °C and washed with PBS-T 
before starting the co-incubation with CAR T cells. As controls, effector cells and 
tumor cells alone were incubated in the same conditions. Every reaction was 
performed in triplicates.  
To determine the amount of secreted IFNγ and IL-2 present in the supernatant after 
the induction of CAR T cell activation, an IFNγ and IL-2 ELISA kit was respectively 
used according to manufacturer´s instruction. 
A half area 96 well plate was coated with capture antibody diluted in coating buffer 
and incubated overnight at 4 °C. After washing three times with PBS-T, blocking of 
the plate was performed with assay diluent for one hour at room temperature. After 
three further washing steps with PBS-T, 30 µl supernatant of the 48 h co-incubation 
and corresponding standard (99 ng/ml) was applied on the blocked plate and 
incubated in the dark for two hours at room temperature. Samples were then 
removed and the plate washed again five times with PBS-T. To detect the cytokines, 
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detection antibody and streptavidin conjugated HRP were mixed (1:1) in assay 
diluent and applied on the plate for one hour at room temperature. Unspecific 
antibody and streptavidin were removed by washing seven times with PBS-T. 
Specific detection antibody bind to HRP conjugated streptavidin was detected with 
TMB substrate reagent. After 30 min incubation, the reaction was stopped with 
sulfuric acid and the plate analyzed with a spectrophotometer.  
 
2.5 Lentiviral gene transfer 
2.5.1 Co-transfection of HEK-293T cells 
The production of lentivirus in the cell culture supernatant was performed over five 
days by co-transfecting HEK-293T cells.  
DAY 1: 
On 15 cm culture plates, 6x106 HEK-293T cells were seeded in 22 ml DMEM 
medium with 10% (v/v) FBS, 100 U/ml penicillin and 100 µg/ml streptomycin pro plate 
and incubated at 37 °C and 5% CO2. After 48 h, cells were grown with a confluence 
of 80% which is optimal for co-transfection.  
DAY 3:  
For the transfection using polyethelinimine (PEI) as transfection reagent, DNA and 
PEI mixtures were separately prepared. The DNA preparation comprised DNA of the 
lentivirus vector of interest, helper plasmid #1 and #2 as well as NaCl and H2O. The 
PEI preparation consisted of PEI, NaCl and H2O. Amounts of the different 
components for the transfection of 5 and 10 plates are indicated in Table 21. The PEI 
mixture is added to the DNA preparation, the entire solution shortly vortex and 
incubated for 10 min at room temperature. 
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Table 21: Transfection components 
Mix Component For 5 plates For 10 plates 
DNA mix 
Lentiviral DNA plasmid of interest 
Helper plasmid #1 
Helper plasmid #2 
NaCl (300 mM) 
H2O 
112.5 µg 
39.5 µg 
73 µg 
3950 µl 
3950 µl 
225 µg 
79 µg 
146 µg 
7900 µl 
7900 µ 
PEI mix 
PEI  (7.5 mM) 
NaCl (300 mM) 
H2O 
1760 µl 
3950 µl 
2190 µ 
3520 µl 
7900 µl 
4380 µl 
Total  16025 µl 32050 µl 
 
Transfection mix was added drop wise to the confluent cells, plates were then slowly 
rotated to spread the transfection mix over the cells and placed back in the incubator 
for 24 h at 37 °C and 5% CO2. 
DAY 4: 
To enable the liberation of lentiviral particles in the supernatant, cell culture medium 
was removed and the cells washed with 5 ml PBS. Fresh DMEM medium (14 ml) with 
100 U/ml penicillin and 100 µg/ml streptomycin but without FBS was slowly added on 
one side of the plate without removing the cells. Incubation over 24 h at 37 °C and 
5% CO2 allowing the secretion of lentivirus in the supernatant. 
DAY 5: 
Harvest and concentration of lentivirus secreted in the supernatant was performed 
with centricons Plus-70 Centrifugal Filter units. 
Remaining cells were first removed by centrifuging the supernatant at 1800 rpm for 
15 min. After transferring the supernatant into a centricon, centrifugation was 
performed at 3500 g for 30 min and the flow through discarded. Concentrated 
lentivirus was removed from the filter by centrifuging the reversed centricon at 1000 g 
for 2 min. The obtained volume was used for the titration, separated in aliquots and 
stored at -80 °C. 
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2.5.2 Lentiviral titration 
One day before the titration, 6 wells of a 24 well plate were seeded with 
5x104 HEK-293T cells pro ml DMEM with 10% (v/v) FBS and 100 U/ml penicillin and 
100 µg/ml streptomycin and incubated for 24 h at 37 °C and 5% CO2.  
Polybrene (8 µg/ml), a cationic polymer used to increase the efficiency of lentiviral 
gene transfer was mixed with different amount of lentivirus (3 µl, 1 µl, 0.3 µl, 0.1 µl) 
and added to the seeded HEK-293T cells. As a control, polybrene without the 
addition of lentivirus was used.  
After 72 h of incubation at 37 °C and 5% CO2, the titer of the lentivirus production 
was determined by flow cytometry (method 2.4.6). Therefore the percentage of target 
cells (100 000 cells) positively expressing the CAR on their surface was determined 
when adding 1 µl of lentivirus. The titer corresponding to the infection unit (IU) per ml 
was then calculated with the following formula: 
   
Titer (IU / ml) =  
 
 
2.5.3 Lentiviral transduction of activated T cells 
Activated T cells were centrifuged at 1400 rpm for 4 min and resuspended in 
pre-warmed X-Vivo 20 medium with IL-2 (300 U/ml). A standing T25 or T75 cell 
culture flask was respectively used for the transduction of 4 to 5x106 T cells or 1 to 
4x107 T cells. Lentivirus with a multiplicity of infection of 10 (MOI 10) and polybrene 
(8 µg/ml) were added to the cell suspension before an incubation period of 24 h at 
37 °C. For the expansion of the transduced T cells, culture medium was removed, 
replaced by fresh X-Vivo 20 medium with IL-2 and the cell suspension incubated for 
further 24 h in the same conditions. Finally the efficiency of the CAR expression was 
determined by flow cytometry (method 2.4.6) and the transduced T cells used to 
perform an apoptosis or an ELISA assay. 
 
Number of target cells (105 cells) x (% of positive cells / 100) 
X 103 
Volume of added lentivirus (1µl) 
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2.6 Preliminary experiments in mice 
2.6.1 Injection of tumor cells 
Mice obtained from Envigo were six to eight weeks old. The animals were maintained 
in filtered cages in a day-night rhythm of 12 hours. Nalm-6 luciferase tumor cells were 
centrifuged at 100 g for 8 min. Obtained pellet was washed twice with PBS and then 
desired amount of cells (1x106 or 5x106 cells) resuspended in 100 µl PBS. For the 
xenotransplantation, tumor cells were injected intravenously into the mice.  
 
2.6.2 Bioluminescence measurement 
Disseminated tumor growth of luciferase transfected tumor cells were followed in vivo 
by bioluminescence imaging. For this purpose, 3 mg of the luciferase substrate 
Luciferin-EF were diluted in 200 µl PBS and injected intraperitoneally in each mouse. 
Animals were anesthetized with 1.5% isoflurane and transferred in the photon-imager 
also connected to the anesthetic gas. Measurement was started 10 min after the 
luciferin injection and the emitted photons recorded during 2 min. After the 
measurement, a photography of the animals was superposed to the obtained 
bioluminescence signal and an equivalent region of interest was selected around 
each mouse. Based on this region, the number of emitted photons for each mouse 
was measured. For the quantitative analysis of the luciferase activity, the measured 
number of photons per minute was used.  
 
2.7 Statistical analysis and graphical representation 
Statistical analysis was performed with the GraphPad Prism 5.0 software. An 
unpaired, two-tailed T test was used to investigate the statistical significance between 
the specific tumor cell lysis and the cytokines secretion of the different CAR 
constructs. A p value < 0.05 was considered to be statistically significant. Graphs 
were created with the GraphPad Prism 5.0 software. Represented error bars showed 
the standard deviation applied to the means.  
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3 Results 
Small format antibody fragments are characterized by high target specificity but may 
suffer from limited biophysical properties such as aggregation or low thermal stability. 
To increase their biophysical robustness, a linker peptide or a disulfide bridge, 
resulting in a single chain variable fragment (scFv) or a disulfide-bond stabilized Fv 
(dsFv), respectively, can be introduced.  
In the present thesis, a new anti-CD22 CAR was developed and further optimized for 
clinical translation by mutagenesis. The targeting domain of the newly constructed  
CAR is composed of a humanized anti-CD22 (hCD22) scFv, which was generated by 
grafting the specificity of the clinically established murine anti-CD22 antibody named 
RFB4 to a phage display isolated stable human framework (Krauss et al., 2003b). 
The resulting antibody fragment shows high affinity for its target antigen CD22 as well 
as an exceptional high biophysical stability. Since the murine anti-CD22 (mCD22) 
scFv of RFB4 is used as control in the present work, we first investigated the stability 
of the mCD22 scFv targeting domain compared to the hCD22 scFv. 
 
3.1 Stability of the murine and humanized anti-CD22 scFv targeting 
domain 
3.1.1 Cloning of the murine anti-CD22 scFv 
To compare the high thermal robustness of the hCD22 scFv at body temperature 
(Krauss et al., 2003b) to its murine counterpart, stability tests were performed. For 
the transient production of the mCD22 antibody fragment, DNA encoding the scFv 
fragment (purchased from Eurofins) was cloned into the mammalian expression 
vector pEE12.4 via a three step procedure involving the subcloning vector pEUC6B 
(Figure 7). To create matching overhangs for subcloning, the restriction sites PvuII 
and BamHI were introduced into the 5’ and 3’ end of the mCD22 gene sequence by 
PCR using the primer set RFB4_1 and RFB4_2 (method 2.2.6). Amplified PCR 
products and the subcloning vector were subsequently digested with both enzymes 
and ligated, resulting in a vector coding for the mCD22 scFv linked to a His6- and 
c-myc tag. The sequence located at the 5’ end of the antibody fragment coded for the 
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IgG-VH leader peptide, which ensures the secretion of the expressed protein in the 
supernatant of transfected mammalian cells (Krauss et al., 2005a). Following control 
digestion and sequencing, which confirmed the correct integration of the insert, the 
gene cassette was cloned into the mammalian expression vector pEE12.4 using 
EcoRI restriction sites. After the identification of a clone with a sense oriented insert 
by enzymatic digestion, plasmid DNA was prepared in high amounts for transfection. 
 
 
Figure 7: Schematic representation of the cloning strategy for the murine anti-CD22 scFv. 
mCD22 scFv was cloned into the expression vector pEE12.4 in three steps. 1: Restriction sites PvuII 
and BamHI were respectively added to the 5’ and 3’ end of the mCD22 antibody fragment gene by 
PCR. 2: The PCR product was inserted into the subcloning vector pEUC6B between the leader 
sequence and the His6-tag using the restriction enzymes PvuII and BamHI. 3: The gene cassette 
encoding the leader peptide, the mCD22 scFv, the His6- and c-myc tag was finally cloned way into the 
expression vector pEE12.4 using EcoRI sites. 
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3.1.2 Expression and purification of the murine anti-CD22 scFv 
The recombinant mCD22 scFv was produced by transiently transfected eukaryotic 
HEK-293-E cells (method 2.3.4). The purification of the antibody fragment from the 
cell culture supernatant was performed by IMAC (method 2.4.1) via the included 
His6-tag sequence (Figure 8A). Unspecifically bound proteins were detached from the 
column with a buffer of low stringency (imidazole concentration of 10 mM). The scFv 
was eluted with a linear gradient of increasing imidazole concentrations. The 
subsequent analysis of the elution fractions via SDS-PAGE (Figure 8C; lane 3) 
revealed the desired scFv protein band at 28 kDa and some unspecific protein 
impurities. In a following purification step via size exclusion chromatography (SEC), 
the scFv containing IMAC fractions were pooled and loaded on a HiLoad Superdex 
75 column to separate scFv from these impurities (method 2.4.2). The size exclusion 
chromatogram revealed two peaks (Figure 8B). Multimeric proteins and aggregates 
eluted at a volume of approximately 50 ml. The second peak with an apparent 
molecular mass of 28 kDa (volume = 70 ml) corresponded to the monomeric scFv. 
Coomassie blue stained SDS-PAGE (Figure 8C; lane 4) and western blot (Figure 8D; 
lane 4) confirmed the high purity of the monomeric antibody fraction. After 
purification, the protein yield obtained for the mCD22 antibody fragment was 0.9 mg/l. 
The purity of monomeric hCD22 scFv previously produced in our laboratory was 
confirmed in parallel to purified mCD22 scFv by analytical SEC using a Superdex 
200 column (Figure 8E and 8F). Both antibody fragments eluted as one single peak 
at 16 ml corresponding to the purified monomeric fraction. 
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Figure 8: Purification of mCD22 scFv. A: IMAC purification chromatogram of the mCD22 scFv: the 
first peak contains unspecific proteins whereas the second peak corresponds to the eluted mCD22 
scFv. B: Size exclusion chromatogram of the IMAC eluate using a Superdex 75 column: multimeric 
proteins and aggregates eluted within the first peak (volume=50 ml). The second peak corresponds to 
the monomeric mCD22 scFv. C: Detection by SDS-PAGE and coomassie blue staining of the IMAC 
flow through (1), IMAC peak 1 (2) and peak 2 (3) and final SEC purified mCD22 scFv (4). L: protein 
ladder. D: Western blot analysis with an anti His6-tag antibody of the IMAC flow through (1), IMAC 
peak 1 (2) and peak 2 (3) and final SEC purified mCD22 scFv (4). L: protein ladder. E: Analytical SEC 
chromatogram of purified mCD22 scFv eluted in a single peak. F: Analytical SEC chromatogram of 
purified hCD22 scFv eluted in a single peak. 
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3.1.3 Stability test of the murine and humanized anti-CD22 scFv 
The stability of purified mCD22 scFv and hCD22 scFv was assessed by flow 
cytometry, measuring their binding activity to living CD22+ Raji cells after an 
incubation period of 7 days (168 h) at 37 °C in 90% human serum (method 2.3.5). At 
all-time points, high binding activity was detected for the hCD22 scFv as well as for 
its murine counterpart (Figure 9A). The analogue experiment performed in PBS 
revealed full binding activity for both scFvs throughout the whole experiment 
(Figure 9B).  
 
Figure 9: Serum and PBS stability of the humanized and murine anti-CD22 scFv. Binding activity 
of hCD22 scFv and mCD22 scFv to CD22+ Raji cells, after 7 days incubation, at 37°C, in human 
serum (A) or PBS (B). Binding activity was measured by flow cytometry and indicated as percentage 
of initial median fluorescence intensity (MFImax). 
 
3.2 Stability of derived CAR constructs  
3.2.1 Generation and expression of the hCD22 scFv-(hFc-28BBz) CAR 
The generation of the hCD22 scFv-(hFc-28BBz) CAR and its expression on T cells 
was chosen as an example to illustrate the construction of all the CAR constructs 
used in the present thesis. 
The DNA cassette coding for the IgG-VH leader sequence and the hCD22 scFv was 
extracted from the subcloning vector pEUC6B by digestion with NcoI and BamHI and 
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further used as template for a PCR reaction with the primer pair hCD22_1 and 
hCD22_2 to replace the restriction site BamHI with NotI at the 3’ end (Figure 10A). 
The amplified PCR product was then inserted into the pENTR vector 5’ to the gene 
encoding the CAR backbone (hFc-28BBz) employing the restriction sites NcoI and 
NotI (Figure 10B). Transformed kanamycin resistant bacterial clones were analyzed 
by sequencing using the sequencing primers pENTR sense and pENTR AS. Plasmid 
DNA from one clone, presenting the correct sequence, was mixed to the DNA of the 
destination vector and a gateway reaction was performed using the LR clonase 
(method 2.2.8). The DNA sequence, located between the attL1 and attL2 sites, was 
in this way integrated into the destination vector between the attR1 and attR2 sites, 
resulting in a final expression clone. Success of this reaction was assessed by 
analytical digestion of the resulting carbenicillin resistant expression clones with KpnI 
via the detection of three distinct DNA fragments at 1462 bp, 2461 bp and 6332 bp 
(Figure 10C). 
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Figure 10: Cloning strategy for the hCD22 scFv-(hFc-28BBz) CAR. A: Schematic representation of 
the cloning strategy: the gene sequence encoding for the leader peptide and hCD22 scFv was 
extracted from the vector pEUC6B using NcoI and BamHI as restriction and ligation sites (1). The PCR 
reaction involving the primer pair hCD22_1 and hCD22_2 enables the replacement of the 3’ restriction 
site BamHI by NotI (2). The amplified PCR product was cloned into the pENTR vector 5’ to the gene 
encoding the CAR backbone employing NcoI and NotI. This cloning step resulted in the generation of 
the entry clone for the gateway reaction (3). DNA of the entry clone vector (pENTR) containing the 
CAR gene was combined with the destination vector to perform the gateway reaction via the LR 
clonase resulting in a final CAR expression clone (4). B: Agarose gel (1%) of the linearized (NcoI) 
(lane 3) and digested (NcoI/NotI) entry clone vector (pENTR) to confirm proper ligation of the scFv 
gene (lane 4), 1 kb marker (lane 1) and 100 bp marker (lane 2), before sequencing. C: Agarose gel 
(1%) showing the analytical digestion of the final hCD22 CAR expression clone with KpnI resulting in 
three distinct DNA bands: 1462 bp, 2461 bp and 6332 bp (3), 1 kb marker (1) and 100 bp marker (2). 
 
For the expression of CAR constructs, T cells were freshly isolated from the blood of 
healthy donors and stimulated with the anti-CD3 antibody OKT-3 and the cytokine 
IL-2 (method 2.3.8 and 2.3.9). Activated T cells were then transduced with lentiviral 
particles containing the CAR gene with a multiplicity of infection (MOI) of 10 (method 
2.5.3). Lentiviral particles were produced in the eukaryotic HEK-293T cell line which 
was transiently transfected with CAR DNA (pRRL vector) and the helper plasmids #1 
and #2 (method 2.5.1). Transduction efficacy of T cells was assessed by flow 
cytometry after 48 h of culture, in the presence of IL-2 (method 2.3.6). The 
percentage of CAR expression on the surface of T cells was then compared to 
non-transduced T cells (mock). While a FITC conjugated anti-CD3 antibody enabled 
the detection of T cells, a phycoerythrin (PE) conjugated anti-human IgG (hFc 
53 
 
specific) antibody was used to detect the CAR. Dependent on the CAR construct, 
CAR T cell expression varied between 10% and 60%. The hCD22 CAR was 
expressed on 64% of T cells, corresponding to a very high expression rate 
(Figure 11). 
 
Figure 11: Flow cytometry analysis to detect the expression of hCD22 CAR on the surface of 
human T cells. T cells from a healthy donor were transduced with lentivirus encoding the hCD22 CAR 
expression vector. After 48 h, non-transduced (left) and CAR transduced T cells (right) were incubated 
with a PE conjugated anti-human IgG antibody, specifically binding the hFc spacer domain of the 
CAR, and a FITC conjugated anti-CD3 antibody. Specific antibody binding was measured by flow 
cytometry. Based on the total amount of T cells, the percentage indicates the proportion of T cells 
expressing the CAR.  
 
3.2.2 Stability of the hCD22 scFv-(hFc-28BBz) and mCD22 scFv-(hFc-28BBz) 
CAR 
The hCD22 scFv-(hFc-28BBz) and mCD22 scFv-(hFc-28BBz) CAR (Figure 12A) was 
generated for the investigation of CAR stability by measuring CAR mediated T cell 
activation towards a cell line expressing the antigen CD22. Secretion of IFNγ in the 
supernatant of the co-culture was used as readout of the T cell activation. Due to the 
difference of positively expressing hCD22 and mCD22 CAR T cell fractions, the 
amount of transduced CAR T cells was adjusted in order to incubate the same 
quantity of positively expressing CAR T cells. 
Activation of T cells through hCD22 and mCD22 CAR was induced by co-incubating 
CAR positive T cells with the CD22 positive human cell line Raji. The amount of 
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secreted IFNγ present in the supernatant of the co-culture was measured after 48 h 
by ELISA (method 2.4.8). To show specificity, transduced T cells were also incubated 
with CD22 negative Jurkat cells.  
The amount of IFNγ release obtained after the incubation of transduced T cells 
without target cells (Figure 12B) was subtracted from the co-culture conditions before 
plotting. At an effector-to-target ratio of 1:2 both mCD22 and hCD22 CAR T cells 
were able to induce a significant IFNγ secretion compared to non-transduced T cells 
(mock) when incubated with Raji cells (Figure 12C). However, the IFNγ release of 
mCD22 CAR T cells was three fold higher than for hCD22 CAR T cells. When 
cultivated with Jurkat cells, mCD22 and hCD22 CAR T cells induced no IFNγ 
secretion.  
Both, hCD22 and mCD22 CARs show high specificity for their target CD22. Human 
T cells expressing these constructs are specifically activated when stimulated by 
CD22 positive cells. Besides CD22, Raji cells also express the human Fc receptor on 
their surface. Therefore, off-target activation of CD22 CAR T cells can occur through 
binding of the hFc spacer domain of the CAR to the hFc receptor expressed on Raji 
cells and influence the observed IFNγ secretion.  
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Figure 12: Activation of hCD22 scFv-(hFc-28BBz) and mCD22 scFv-(hFc-28BBz) CAR T cells. 
A: Schematic representation of the hCD22 and mCD22 CAR. B: Through lentiviral gene transfer, 
isolated T cells from a healthy donor were equipped with the hCD22 or the mCD22 CAR. As control, 
hCD22 CAR and mCD22 CAR transduced T cells and non-transduced T cells (mock; 
0.375x104 - 3x104 cells per well) were incubated without target cells. IFNγ secretion was used as read 
out for CAR T cell activation and measured by ELISA in the supernatant of the co-culture. C: To 
assess specific CAR T cell activation, hCD22 CAR and mCD22 CAR transduced T cells and 
non-transduced T cells (0.375x104 - 3x104 cells per well) were co-incubated with Raji cells (left) or 
Jurkat cells (right, 3x104 cells per well). Amount of secreted IFNγ obtained for transduced and 
non-transduced T cells only was subtracted before plotting. Data represent the mean of triplicates 
± standard deviation. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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To avoid off-target activation and to enable the stability analysis by measuring the 
specific hCD22 and mCD22 CAR T cell, the hFc spacer was replaced by a CD8 
spacer domain resulting in two new constructs: hCD22 scFv-(CD8-28BBz) CAR and 
mCD22 scFv-(CD8-28BBz) CAR (Figure 13A). Furthermore, Raji cells were replaced 
by the tumor cell line Nalm-6, which expresses CD22 but lacks the hFc receptor. 
CAR generation was performed, as previously described, by using a destination 
vector encoding for a CAR backbone with CD8 as spacer domain. Transduction 
efficacy was assessed by flow cytometry using a FITC conjugated anti-CD3 antibody 
to detect T cells and a biotin-alexa 488 conjugated streptavidin detection system to 
identify the variable light chain of the scFv present on the CAR. 
 
Figure 13: Activation of hCD22 scFv-(CD8-28BBz) and mCD22 scFv-(CD8-28BBz) CAR T cells. 
A: Schematic representation of the hCD22 and mCD22 CAR with the CD8 spacer domain instead of 
the hFc spacer. B: Through lentiviral gene transfer, isolated T cells from a healthy donor were 
equipped with the hCD22 or the mCD22 CAR. To assess specific CAR T cell activation, hCD22 CAR 
and mCD22 CAR transduced T cells and non-transduced T cells (0.375x104 - 3x104 cells per well) 
were co-incubated with Nalm-6 cells (left) or Jurkat cells (right, 3x104 cells per well). IFNγ secretion 
was used as read out for CAR T cell activation and measured by ELISA in the supernatant of the 
co-culture. Data represent the mean of triplicates ± standard deviation. * P < 0.05; ** P < 0.01; 
*** P < 0.001. 
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At an effector-to-target ratio of 1:2, significantly increased IFNγ amounts were 
detected in the supernatant of activated murine and humanized CD22 CAR 
transduced T cells in comparison to non-transduced T cells after 48 h of cultivation 
with Nalm-6 cells (Figure 13B). Co-cultured with Jurkat cells, T cells equipped with 
the murine and humanized CD22 CAR showed no increase in IFNγ secretion. The 
specific activation of T cells expressing the murine and humanized CD22 CAR was 
triggered by CD22 positive Nalm-6 cells, demonstrating biophysical stability of both 
scFv derived CARs. 
 
3.3 Optimization of the hCD22 scFv-(hFc-28BBz) CAR by 
mutagenesis 
3.3.1 Generation of two single and a double mutant of hCD22 scFv-(hFc-
28BBz) CAR 
The success of ongoing clinical trials shows that, CAR engineered T cells are potent 
and in general well tolerated. However, for their broader use, new approaches have 
to be developed to prevent serious adverse events, such as cytokine release 
syndrome or on-target, off-tumor toxicity (Brentjens et al., 2011b; Morgan et al., 
2010). To increase CAR safety, solutions such as improved tumor selectivity by 
combinatorial signaling (Kloss et al., 2013), a deeper understanding of cytokine 
storms, the development of trigger and elimination mechanisms or the 
implementation of on/off switching systems (Juillerat et al., 2016) are currently 
emerging. Another approach is to focus on the CAR design itself (Maus and Powell, 
2015). The use of different components or specific mutations inside CAR domains 
allows the development of highly effective tumor-specific T cells with an optimal 
activation.  
To enhance the safety of the parental hCD22 scFv-(hFc-28BBz) CAR (hCD22 CAR), 
the Fcγ receptors (FcγR) and LCK binding domains were mutated/inactivated by 
site-directed mutagenesis of the hFc spacer and the CD28 co-stimulatory domain, 
resulting in two mutants referred to as hCD22 scFv-(ΔhFc-28BBz) CAR (simplified as 
ΔFc hCD22 CAR) and hCD22 scFv-(hFc-Δ28BBz) CAR (simplified as 
ΔCD28 hCD22 CAR) and one double mutant hCD22 scFv-(ΔhFc-Δ28BBz) CAR 
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(simplified as ΔFc-ΔCD28 hCD22 CAR) in which both mutations were simultaneously 
expressed (Figure 14).  
 
Figure 14: Schematic representation of parental and mutated hCD22 CAR sequences. The 
hCD22 scFv-(ΔhFc-28BBz) CAR is mutated in the CH2 domain of the hFc spacer to prevent off-target 
activation of innate immune cells. The deletion of the LCK binding region in the 
hCD22 scFv-(hFc-Δ28BBz) CAR blocks IL-2 secretion. The hCD22 scFv-(ΔhFc-Δ28BBz) CAR 
combines both mutations in one construct. 
 
To generate the ΔFc hCD22 CAR and ΔCD28 hCD22 CAR variants, mutations were 
introduced by site-directed mutagenesis using the parental hCD22 entry clone vector 
(pENTR) as template with either the mutagenic primer combination CD28_Lck-Fw 
and CD28_Lck-Rev or hIgG1_CH2-Fw and hIgG1_CH2-Rev (method 2.2.7). DNA 
modification of transformed kanamycin resistant bacterial clones was confirmed by 
sequencing using the primers pENTR sense and pENTR AS and further used for the 
gateway reaction. The sequence of the resulting carbenicillin resistant expression 
clone was confirmed by analytical digestion. The double mutated 
hCD22 scFv-(ΔhFc-Δ28BBz) CAR carrying both single mutations was generated by 
site-directed mutagenesis with hIgG1_CH2-Fw and hIgG1_CH2-Rev as mutagenic 
primer pair and DNA of the CD28 single mutated hCD22 entry clone as template. 
 
3.3.2 T cell activation of the mutated CAR variants in vitro 
3.3.2.1 Impact of the mutation within the hFc domain 
To assess the impact of mutating the CH2 domain of the IgG1 Fc spacer, specific 
tumor cell lysis and IFNγ release induced by CAR T cell activation were measured by 
an XTT assay and by ELISA, respectively. For this purpose, the parental, the ΔhFc 
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and ΔFc-ΔCD28 hCD22 CAR T cells were co-incubated with THP-1 cells which 
express the Fcγ receptor (FcγR) but lack CD22 expression. After 24 h, the 
supernatants of the co-cultures were removed for IFNγ measurement and the 
remaining cells were used to quantify CAR T cell mediated tumor cell lysis by XTT 
assay (method 2.3.10). Non-transduced T cells served as controls (mock). 
In contrast to the parental hCD22 CAR, ΔhFc and ΔFc-ΔCD28 hCD22 CAR T cells 
were not activated by binding to THP-1 cells and thus lacked specific tumor cell lysis 
(Figure 15A). Low amounts of IFNγ were observed for the ΔhFc hCD22 CAR T cells 
when incubated with FcγR+ THP-1 cells (Figure 15B). Secretion of this cytokine was 
six times higher for the parental hCD22 CAR T cells in comparison to CAR T cells 
harboring the hFc mutation. 
 
Figure 15: Specific activation by FcγR binding of parental, ΔhFc and ΔhFc-ΔCD28 hCD22 CAR 
T cells. A: Freshly isolated T cells from a healthy donor were equipped with one of the three hCD22 
CAR variants by lentiviral gene transfer and cultured (1x105 cells per well) with THP-1 cells 
(1x105 cells per well). After 24 h, cytotoxicity against THP-1 cells was recorded by XTT assay. 
B: Concentration of secreted IFNγ was quantified by ELISA. Data represent the mean of triplicates 
± standard deviation. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
3.3.2.2 Impact of the mutation within the CD28 domain 
The impact of mutating the intracellular CD28 LCK binding moiety was assessed by 
measuring the amount of secreted IFNγ and IL-2 by ELISA after CAR T cell activation 
(method 2.4.8). IL-2 abrogation is expected to be observed for activated ΔCD28 and 
ΔFc-ΔCD28 hCD22 CAR T cells but not for those with the parental and ΔhFc hCD22 
CARs. While CAR T cell activation (measured by IFNγ release) was observed for all 
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CAR variants, surprisingly, IL-2 could not be detected by ELISA in the supernatant of 
the parental and ΔhFc hCD22 CAR T cells co-cultured with CD22 expressing Nalm-6 
cells (Data not shown). To understand the absence of IL-2 secretion, a previously 
characterized carcinoembryonic antigen (CEA) scFv-(hFc-28zOX40) CAR inducing 
the secretion of IL-2 in high amounts was used as a reference for the following 
experiment. 
 
3.3.2.2.1 T cell activation of CEA scFv-(hFc-28zOX40) and CEA scFv-(hFc-
28BBz) in vitro 
The CEA scFv-(hFc-28zOX40) CAR harbors a CEA antibody fragment as targeting 
moiety on the extracellular site and OX40 as second co-stimulatory domain instead of 
4-1BB which was used in the hCD22 CAR variants in this thesis. To investigate the 
impact of the second co-stimulatory domains OX40 and 4-1BB on IL-2 secretion, a 
new CEA scFv-(hFc-28BBz) CAR including 4-1BB instead of OX40 was generated 
(Figure 16A). NcoI-NotI digested CEA scFv was ligated to the similar digested 
parental hCD22 CAR entry clone encoding for the CAR backbone with 4-1BB. After 
sequencing and performing the gateway reaction with the correct DNA sequence, 
final carbenicillin resistant expression clones were confirmed by analytical digestion. 
After isolation, CD3+ T cells were equipped with both CEA CARs by lentiviral gene 
transfer. 
Activation of transduced T cells was assessed after 48 h of co-incubation with CEA 
expressing MCF-7 cells by quantifying the amount of IFNγ and IL-2 secreted into the 
supernatant of the co-culture. To control the specificity of the activation, CEA CAR 
T cells were incubated with CEA negative HEK-293T cells. In comparison to 
non-transduced T cells, significantly increased IFNγ amounts were detected in the 
supernatant of CEA CAR T cells co-incubated with MCF-7 cells at an effector-to-
target ratio of 1:1 (Figure 16B). Secretion of this cytokine was three times higher for 
activated CEA CAR T cells harboring the OX40 domain than for T cells equipped with 
the CEA CAR comprising 4-1BB.  
As expected, no IFNγ release was induced by transduced T cells incubated with 
antigen negative control cells (HEK-293T). When cultivated with MCF-7 cells, IL-2 
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secretion was only observed in the supernatant of CEA CAR T cells harboring the 
OX40 domain but not for those carrying 4-1BB as second costimulatory signal 
(Figure 16C). No IL-2 was secreted by T cells and CEA CAR T cells after being 
co-incubated with CEA negative HEK-293T cells.  
 
Figure 16: Activation of CEA scFv-(hFc-28BBz) and CEA scFv-(hFc-28zOX40) CAR T cells. 
A: Schematic representation of the CEA CAR constructs incorporating either 4-1BB or OX40 as 
second co-stimulatory domain. B: CD3+ cells were transduced with lentiviral particles containing the 
CEA CAR DNA. MCF-7 cells (left) and HEK-293T cells (right, 3x104 cells per well) were co-cultured for 
48 h with CEA CAR T cells and non-transduced T cells (0.375x104 - 3x104 cells per well) to analyze 
the specific CAR T cell activation. IFNγ levels in the supernatant were measured by ELISA as a read 
out for CAR T cell activation. C: IL-2 levels present in the supernatant were quantified by ELISA. Data 
represent the mean of triplicates ± standard deviation. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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At an effector-to-target ratio of 1:1, the significantly increased IFNγ secretion 
confirmed the specific activation of both CEA CAR T cells by the CEA antigen. While 
the co-stimulatory domain CD28, responsible for IL-2 secretion, is integrated in both 
tested CEA CARs, the type of second-co-stimulatory domain seems to have a direct 
impact on the IL-2 release. The presence of OX40 in combination with CD28 might 
promote the IL-2 secretion compared to 4-1BB. 
 
3.3.2.2.2 T cell activation of hCD22 scFv-(hFc-28zOX40) in vitro 
To investigate if IL-2 secretion is specific to CEA scFv-(hFc-28zOX40) CAR T cells or 
is induced by the presence of the combination CD28-OX40, independently of the 
scFv targeting domain, the hCD22 scFv-(hFc-28zOX40) CAR incorporating the 
hCD22 scFv and the co-stimulatory domains CD28 and OX40 was generated 
(Figure 17 A). 
Isolated T cells equipped with hCD22 CAR harboring either the OX40 or 4-1BB 
domain were compared to each other by analyzing the IFNγ and IL-2 levels present 
in the supernatant after binding to CD22 (method 2.4.8). For this purpose, transduced 
T cells were incubated with coated recombinant hCD22-hFc proteins. After 48 h, the 
level of secreted cytokines was measured by ELISA. To control for non-specific 
activation, hCD22 CAR T cells were also incubated in a control plate coated with the 
hFc protein (Figure 17B). The resulting unspecific activation was subtracted before 
plotting. When incubated on a plate coated with hCD22-hFc, hCD22 CAR T cells 
containing either OX40 or 4-1BB were specifically activated by binding the hCD22 
protein and high IFNγ amounts were detected in the supernatant in comparison to 
T cells without CAR (Figure 17C). Significant IL-2 levels were measured in the 
supernatant of hCD22 CAR T cells presenting OX40 as co-stimulatory domain in 
comparison to non-transduced T cells. No IL-2 was secreted from hCD22 CAR 
T cells containing the 4-1BB domain.  
For CEA scFv-(hFc-28zOX40) and hCD22 scFv-(hFc-28zOX40) CAR T cells, the 
combination of the intracellular co-stimulatory domains seems to be decisive for a 
detectable IL-2 secretion whereas the targeting domain has no influence.  
63 
 
 
Figure 17: Activation of hCD22 scFv-(hFc-28BBz) and hCD22 scFv-(hFc-28zOX40) CAR T cells. 
A: Schematic representation of the hCD22 CAR containing either OX40 or 4-1BB as second 
co-stimulatory domain. B: Through lentiviral gene transfer, isolated T cells from a healthy donor were 
equipped with the hCD22 CARs. To control the specificity, hCD22 CAR transduced T cells and 
non-transduced T cells (0.75x104 - 6x104 cells) were incubated for 48 h with coated hFc proteins. 
Specific CAR T cell activation was assessed by measuring the amount of secreted IFNγ (left) and IL-2 
(right) by ELISA. C: To assess specific CAR T cell activation, hCD22 CAR transduced T cells and 
non-transduced T cells (0.75x104 - 6x104 cells) were incubated for 48 h with coated hCD22-hFc 
proteins. Amount of secreted IFNγ and IL-2 obtained for transduced and non-transduced T cells 
incubated with coated hFc proteins was deduced before plotting. Data represent the mean of 
triplicates ± standard deviation. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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3.3.2.3 In vitro cytotoxicity analysis of the mutated CAR variants 
In this approach, the T cell activation of parental and mutated hCD22 CARs was 
characterized in vitro in order to select the lead candidate for further in vivo studies. 
An IFNγ ELISA was performed to assess if CAR T cells are specifically activated 
through CD22 positive Nalm-6 cells and an apoptosis assay allowed the investigation 
of target induced tumor cell lysis. Taking into account natural T cell variability, T cells 
from three healthy donors were tested independently.  
Purified donor T cells were modified ex vivo by lentiviral gene transfer with either the 
parental, the ΔhFc, the ΔCD28 or the ΔFc-ΔCD28 hCD22 CARs. Expression of the 
four different CAR variants on the surface of T cells was determined by flow 
cytometry with an APC conjugated anti-CD3 antibody, recognizing CD3+ T cells, and 
a PE-conjugated IgG1 antibody detecting the parental and the mutated hFc spacer 
domain of the CAR.  
The relative number of T cells expressing the hCD22 CAR variants differed for each 
donor within a range from 10% to 60% (Table 22). The highest expressing hCD22 
CAR T cells were obtained for donor 1 whereas the relative CAR expression on 
T cells from donor 3 was the lowest. Within each donor, the expression levels among 
the different CAR constructs varied around 10%. 
Table 22: Expression of hCD22 CAR variants on the surface of T cells from three donors. 
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For each donor, the different hCD22 CAR T cells were incubated with the CD22 
positive target cell line Nalm-6 at an effector-to-target ratio of 1:1 to measure the 
specific CAR T cell activation. To enable a comparison among the hCD22 CAR 
variants while their expression levels are different, the amounts of hCD22 CAR 
T cells were adjusted to incubate the same quantity of positively expressing CAR 
T cells. To assess the specific activation, CAR T cells were also cultivated alone 
(w/o) and with target negative Jurkat cells. After 24 h or 48 h, the supernatant of the 
co-culture was removed for IFNγ measurement and the remaining cells were used to 
quantify CAR T cell mediated tumor cell lysis by flow cytometry (method 2.3.7). CD22 
positive Nalm-6 cells were identified by a PE-Cy7 conjugated anti-CD19 antibody and 
both T cells as well as Jurkat cells by a pacific-blue conjugated anti-CD3 antibody. 
Nalm-6 cell death was detected by the combination of the apoptotic markers, namely 
FITC conjugated annexin V and propidium iodide (PI) for the first and second donor 
and by caspase 3 for the third donor in order to validate cytotoxicity via a second 
detection system. 
For donor 1, all three hCD22 CAR T cell variants triggered the lysis of CD22 positive 
Nalm-6 but had no cytotoxic effect on CD22 negative Jurkat cells (Figure 18A). 
T cells transduced with the parental hCD22 CAR induced 20% higher tumor cell lysis 
than ΔhFc and ΔCD28 hCD22 CAR T cells. CD3+ cells expressing the double mutant 
ΔFc-ΔCD28 hCD22 construct showed the lowest lytic activity. Significantly more IFNγ 
was detected in the supernatant of T cells with the parental CAR after cultivation with 
Nalm-6 cells compared to the supernatant of mutated CAR T cells (Figure 18B). 
Double mutant ΔFc-ΔCD28 hCD22 CAR T cells induced the lowest cytokine release. 
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Figure 18: Specific activation of parental and mutated hCD22 CAR expressing T cells from 
donor 1. A: Freshly isolated T cells from donor 1 were transduced with lentivirus particles containing 
one of the four hCD22 CAR variant genes and cultured (1x105 cells per well) either alone (w/o; left), 
with Nalm-6 (middle) or with Jurkat cells (right; 1x105 cells per well). After 48 h, co-cultivated cells 
were stained with an anti-CD19 antibody, an anti-CD3 antibody, annexin V and PI to determine tumor 
cell lysis by flow cytometry. B: The concentration of IFNγ present in the supernatant was measured by 
ELISA. Data represent the mean of triplicates ± standard deviation. * P < 0.05; ** P < 0.01; 
*** P < 0.001. 
 
For the second donor, Nalm-6 cell lysis was mediated by T cells equipped with each 
of the four hCD22 CAR variants whereas no lytic activity was observed after 
co-incubation with Jurkat cells (Figure 19A). T cells expressing either the parental, 
the ΔhFc or the ΔCD28 hCD22 CARs showed a similar lytic activity. The hCD22 CAR 
T cells carrying a mutated spacer and a mutated CD28 domain lysed a lower amount 
of tumor cells. IFNγ secretion was detected for all hCD22 CAR variant T cells 
co-incubated with Nalm-6 cells (Figure 19B). For this donor and contrary to donor 1, 
a relatively high amount of IFNγ was measured for non-transduced T cells (mock) 
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when incubated with Nalm-6 cells which is probably due to alloreactive T cells. When 
incubated with Jurkat cells, no IFNγ secretion was detected. 
 
Figure 19: Specific activation of parental and mutated hCD22 CAR expressing T cells from 
donor 2. A: Isolated T cells from donor 2 were equipped with one of the four hCD22 CAR variants by 
lentiviral gene transfer. CAR T cells (1x105 cells per well) were cultured either alone (w/o; left), with 
Nalm-6 (middle) or with Jurkat cells (right; 1x105 cells per well). After 48 h, tumor cell lysis was 
assessed by flow cytometry. Cultivated cells were stained with an anti-CD19 antibody, an anti-CD3 
antibody, annexin V and PI. B: Secretion of IFNγ in the supernatant was evaluated by ELISA. Data 
represent the mean of triplicates ± standard deviation. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
For the third donor, specific tumor cell lysis was assessed by the IntelliCyt HTFC 
screening system measuring the apoptotic marker caspase 3. Mutated hCD22 CAR 
T cells triggered a specific Nalm-6 cell lysis compared to T cells without CAR 
(Figure 20A). For this donor, the lytic activity of the ΔFc-ΔCD28 double mutated 
hCD22 CAR T cells was as high as for the ΔFc and for the ΔCD28 mutated CAR 
T cells. T cells transduced with the parental hCD22 CAR showed no significant tumor 
cell lysis in comparison to non-transduced T cells. An alloreaction of these original 
T cells might be responsible for the high level of observed cytotoxicity. In the 
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supernatant of mutated hCD22 CAR T cells incubated with Nalm-6 cells, high 
amounts of IFNγ were measured (Figure 20B). When incubated with CD22+ tumor 
cells, no significant cytokine levels were detected for T cells expressing the parental 
CAR variant in comparison to T cells without CAR.  
Parental hCD22 CAR T cell activation has already been shown in earlier experiments 
through specific tumor cell lysis for donor 1 and 2 as well as through IFNγ secretion. 
Therefore, for this donor, the lack of a significant activation is probably due to a 
combination of alloreactive T cells and a problem in the experimental progress. 
 
Figure 20: Specific activation of parental and mutated hCD22 CAR expressing T cells from 
donor 3. A: Freshly isolated T cells from donor 3 were equipped with the four hCD22 CAR variants by 
lentiviral gene transfer and cultured (1x105 cells per well) with Nalm-6 cells (1x105 cells per well). After 
24 h, specific tumor cell lysis was determined via the IntelliCyt HTFC Screening System by measuring 
the apoptotic marker caspase 3. B: Concentration of secreted IFNγ was quantified by the IntelliCyt 
HTFC Screening System. Data represent the mean of triplicates ± standard deviation. * P < 0.05; 
** P < 0.01; *** P < 0.001. 
 
Using two distinct detection methods, T cell activation mediated by the parental and 
the mutated hCD22 CARs was confirmed with T cells from different donors. 
Introduction of the mutation in the hFc or the CD28 domain had no influence on the 
capacity of hCD22 CAR T cells to induce lytic activity against CD22 positive tumor 
cells. Nevertheless, by mutating the spacer and the domain responsible for IL-2 
secretion, the lytic activity of the double mutated ΔFc-ΔCD28 hCD22 CAR was 
reduced in comparison to the ΔFc or ΔCD28 mutated ones. 
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Successful clinical development of a CAR T cell therapy is strongly related to the 
prevention and management of unwanted CAR toxicity (Bonifant et al., 2016). To 
improve CAR safety, toxic effects following CAR T cell infusion have to be minimized. 
Therefore, based on its lower lytic activity and on its innovative aspect by combining 
the hFc and CD28 mutations, the hCD22 scFv-(ΔhFc-Δ28BBz) CAR is selected as 
lead candidate for further in vivo studies. 
 
3.4 Characterization of the lead candidate and preliminary in vivo 
studies 
3.4.1 Selection of a CAR lead candidate for in vivo studies 
3.4.1.1 Generation of the hCD22 (L36Y) scFv-(∆hFc-∆28BBz) CAR 
Previously, for the generation of an anti-CD22 derived dimeric immunoenzyme, 
a hCD22 diabody was created by reducing the size of the linker peptide (Krauss et 
al., 2005b). Early bacterial production of this hCD22 diabody resulted in high 
aggregation levels. Due to the formation of multimeric molecules, the soluble 
expression and purification of the diabody-RNase fusion protein was difficult (Krauss 
et al., 2005b). To overcome this problem, the VH-VL interface of the hCD22 diabody 
was engineered by mutating the leucine residue at position 36 to tyrosine, a common 
human amino acid at this location. This amino acid exchange also resulted in 
enhanced solubility and stability of the bivalent molecules. 
Since the properties of the antibody fragment directly affect CAR T cell activation, we 
investigated if the stability of the hCD22 CAR can be enhanced by engineering the 
associated scFv. For this purpose, the engineered hCD22 (L36Y) scFv-
(ΔhFc-Δ28BBz) CAR (simplified as L36Y engineered ΔFc-ΔCD28 hCD22 CAR) was 
generated (Figure 21A). The mutation at position 36 of the VH-VL interface was 
introduced by site directed mutagenesis using hCD22_LY-Fw and hCD22_LY-Rev as 
primer set and the non-engineered double mutant ΔFc-ΔCD28 hCD22 CAR entry 
clone vector (pENTR) as template. The final expression clone was confirmed by 
analytical digestion and further used to produce the corresponding lentiviral particles. 
 
70 
 
3.4.1.2 T cell activation of hCD22 (L36Y) scFv-(∆hFc-∆28BBz) in vitro 
To assess the stability of the L36Y engineered ΔFc-ΔCD28 hCD22 CAR in 
comparison to the ΔFc-ΔCD28 construct, IFNγ secretion was measured after CAR 
T cell activation. T cells isolated from the blood of three healthy donors were used as 
biological triplicates to account for T cell variability. After lentiviral gene transfer, 
transduced T cells were incubated for 48 h on a plate coated with the recombinant 
hCD22-hFc protein. The IFNγ concentration, in the supernatant, was detected by 
ELISA. To analyze unspecific activation, L36Y engineered ΔFc-ΔCD28 and 
ΔFc-ΔCD28 hCD22 CAR T cells were also incubated on a control plate coated with 
the hFc protein only. The resulting unspecific activation was deduced before plotting.  
For the first donor, both hCD22 CAR T cells induced IFNγ release after binding to the 
hCD22 antigen in comparison to T cells without CAR. A higher cytokine concentration 
was measured for T cells expressing the L36Y engineered ΔFc-ΔCD28 hCD22 CAR 
(Figure 21B).   
For the second and third donor, IFNγ secretion was only detected for ΔFc-ΔCD28 
CAR T cells. L36Y engineered CAR T cells did not induce secretion of this cytokine 
when compared to ordinary T cells. 
The mutation in the hCD22 scFv did not enhance the activation of the corresponding 
CAR T cells. The double mutant ΔFc-ΔCD28 hCD22 CAR was therefore kept as lead 
candidate for further in vivo studies. 
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Figure 21: Specific activation of hCD22 scFv-(ΔhFc-Δ28BBz) and hCD22 (L36Y) scFv-
(ΔhFc-Δ28BBz) CAR T cells. A: Schematic representation of the ΔFc-ΔCD28 and L36Y engineered 
ΔFc-ΔCD28 hCD22 CAR. B: Freshly isolated T cells from the blood of three healthy donors were 
transduced with lentiviral particles containing the ΔFc-ΔCD28 or L36Y engineered ΔFc-ΔCD28 CAR 
gene. These CAR T cells and non-transduced T cells (0.75x104 - 3x104 cells) were incubated for 48 h 
on a plate coated with hCD22-hFc protein. Specific activation of CAR T cells was assessed by 
measuring the amount of secreted IFNγ for donor 1 (top left), donor 2 (right) and donor 3 (bottom left) 
present in the supernatant of the co-cultures via ELISA. 
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3.4.2 Generation and T cell activation of mCD22 scFv-(∆hFc-∆28BBz) and HSV 
scFv-(∆hFc-∆28BBz) in vitro 
After completion of the in vitro characterization of the double mutant ΔFc-ΔCD28 
hCD22 CAR, the aim was to characterize the in vivo the efficacy of the construct 
using a xenograft mouse model. As the hCD22 antibody fragment is derived from the 
mCD22 scFv (Krauss et al., 2003b), a double mutant mCD22 CAR (mCD22 scFv-
(∆hFc-∆28BBz)) (ΔFc-ΔCD28 mCD22 CAR) was created and included in the 
experiments for direct comparison (Figure 22A). To control the scFv-independent 
effect of the CAR backbone itself, a double mutant CAR comprising a non-relevant 
anti-herpes simplex virus (HSV) scFv (HSV scFv-(∆hFc-∆28BBz)) (ΔFc-ΔCD28 HSV 
CAR) was generated and used as control. 
The new double mutant ΔFc-ΔCD28 mCD22 and HSV CARs were built by replacing 
the hCD22 scFv with the corresponding antibody moiety in the double mutant entry 
clone. Final expression clones obtained after the gateway reaction were used for 
lentiviral gene transfer. 
Specific activation of double mutant ΔFc-ΔCD28 mCD22 CAR T cells against CD22 
expressing Nalm-6 cells was assessed by measuring induced tumor cell lysis and 
IFNγ secretion. Double mutant ΔFc-ΔCD28 HSV CAR T cells were tested in parallel. 
After lentiviral gene transfer, the same amount of CAR expressing T cells was 
co-incubated with Nalm-6 cells. To control for non-specific CAR mediated activation, 
double mutant ΔFc-ΔCD28 mCD22 and HSV CAR T cells were also cultured alone or 
with target negative Jurkat cells. After 48 h, the concentration of IFNγ in the 
supernatant was determined and the remaining cells were analyzed by flow 
cytometry to quantify CAR T cell mediated tumor cell lysis. CD22 positive Nalm-6 
cells were identified by a PE-Cy7 conjugated anti-CD19 antibody, T cells and Jurkat 
cells by a pacific-blue conjugated anti-CD3 antibody. Lysis of Nalm-6 cells was 
detected by the apoptotic marker combination FITC conjugated annexin V / PI.  
When incubated with CD22 positive Nalm-6 cells, specific tumor cell lysis was 
observed for double mutant ΔFc-ΔCD28 mCD22 CAR T cells in comparison to T cells 
transduced with the ΔFc-ΔCD28 HSV CAR (Figure 22B). No lytic activity was 
detected for double mutant ΔFc-ΔCD28 mCD22 and HSV CAR T cells incubated with 
Jurkat cells confirming the specificity of the ΔFc-ΔCD28 mCD22 CAR. Detected IFNγ 
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levels were significantly higher for double mutant ΔFc-ΔCD28 mCD22 CAR T cells 
than for HSV CAR T cells when co-incubated with Nalm-6 cells (Figure 22C). No 
cytokine secretion was observed for both CAR T cells after co-cultivation with Jurkat 
cells. 
 
Figure 22: In vitro characterization of double mutant mCD22 and HSV CAR expressing T cells.  
A: Schematic representation of the double mutant mCD22 and the double mutant HSV CAR. B: CD3+ 
isolated T cells were transduced with lentivirus encoding either the double mutant mCD22 or HSV 
CAR. CAR T cells (1x105 cells per well) were cultured either alone (w/o; left), with Nalm-6 cells 
(middle) or with Jurkat cells (right; 1x105 cells per well). After 48 h, tumor cell lysis was assessed by 
flow cytometry. Cultivated cells were stained with PE-Cy7 conjugated anti-CD19 antibody, the pacific-
blue conjugated anti-CD3 antibody, FITC conjugated annexin V and PI. C: The concentration of 
secreted IFNγ was determined by ELISA. 
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3.4.3 Preliminary in vivo studies: establishment of a leukemia xenograft in 
NOD-SCID mice 
In order to assess the therapeutic in vivo efficacy of double mutant ΔFc-ΔCD28 
hCD22 and mCD22 CAR T cells in NOD/SCID mice, a disseminated model of 
pre-B-cell acute lymphoblastic leukemia, the CD22 positive Nalm-6 cell line, was 
used. 
Engraftment of tumor cells was first investigated in a preliminary in vivo test. The use 
of stably luciferase transfected Nalm-6 cells (Nalm-6-Luc cells), previously generated 
by Tobias Weber (PhD, University of Heidelberg) allowed the monitoring of the tumor 
progression by non-invasive bioluminescent measurements. Mice with a body weight 
loss of more than 20% or showing tumor related paralysis symptoms were sacrificed. 
Six female NOD/SCID mice (6 - 8 weeks old) were separated into two groups and 
received either 1x106 or 5x106 Nalm-6-Luc cells intravenously. Disseminated tumor 
engraftment was monitored one to two times per week by bioluminescence imaging. 
This non-invasive method is based on light emission resulting from the oxidation of 
D-luciferin by the luciferase enzyme expressed in the tumor cells. Intraperitoneal 
injection of 3 mg of D-luciferin substrate per mouse is followed, after 10 min, by light 
measurement of luciferase transfected leukemia cells. Measured luciferase activity is 
presented as the number of photons detected per minute. 
 
Figure 23: Preliminary in vivo test with a disseminated Nalm-6 xenograft model. Each 
NOD/SCID mouse (M1-M6) received an intravenous injection of 1x106 (black) or 5x106 (green) 
Nalm-6-Luc cells. A: Number of photons detected per minute. Luciferase activity was measured one to 
two times per week starting at day 5. B: Weight progression of each animal. 
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The first bioluminescence imaging was performed five days after xenotransplantation 
(Figure 23A). Until day 27, no tumor progression was observed for all six mice. The 
body weight of the animals, regularly measured after xenotransplantation, remained 
stable over time (Figure 23B). No tumor engraftment could be observed in the 
NOD/SCID mice.  
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4 Discussion 
4.1 CD22 as target for a CAR based therapy 
Over the last decade, the adoptive T cell transfer with chimeric antigen receptor 
(CAR) engineered T cells emerged as a clinically effective therapy to treat 
hematological malignancies. A CAR consists of at least two functional components: 
an extracellular single chain variable fragment (scFv) specifically binding a tumor-
associated antigen (TAA) and an intracellular T cell receptor (TCR) derived signaling 
domain, initiating T cell activation upon target engagement (Eshhar, 2008; Gross et 
al., 1989). To ensure high anti-tumor efficacy and at the same time a low toxicity, the 
target antigen has to be carefully chosen when developing a CAR therapy.  
Nowadays, the most investigated target is CD19 due to its presence in most B cell 
malignancies. Its B cell lineage limited expression (Li et al., 1996) restricts the 
potential of off-target complications. Apart from malignant cells, healthy B cells 
expressing CD19 are likewise destroyed as seen during CD19 CAR T cell therapy, 
resulting in B cell aplasia and hypogammaglobulinemia (Kochenderfer et al., 2012b; 
Porter et al., 2011). This side effect can fortunately be managed by γ-globulin 
infusion as replacement. Unlike CD19, an unwanted outcome occurred with CAR 
T cells therapy targeting the carbonic anhydrase IX (CAIX), a target overexpressed 
on the surface of clear cell renal carcinoma (Lamers et al., 2006). Due to unexpected 
target expression in the biliary tract, for which CAIX transduced CAR T cells showed 
reactivity, liver toxicity was observed in treated patients after therapy.  
In the field of CAR therapy, two second generation CD19 CARs, harboring either the 
co-stimulatory domain CD28 or 4-1BB in addition to CD3ζ have been mainly 
investigated. Preclinical studies showed enhanced antitumor activity compared to the 
CD19 CAR without co-stimulatory domains (Brentjens et al., 2007; Milone et al., 
2009) and the efficacy of both CARs was confirmed in the clinic. A milestone was 
achieved in 2012 with a phase I clinical trial using CD19 CAR T cells carrying the 
co-stimulatory domain 4-1BB when lasting remissions were observed in relapsed 
acute lymphoblastic leukemia patients (Maude et al., 2014). Further phase I clinical 
trials were performed in three independent centers and the treatment of pediatric and 
adult B-ALL patients using CD19 CAR T cells showed complete remission rates 
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within a range of 67 to 90% (Brentjens et al., 2013; Davila et al., 2014; Lee et al., 
2015; Maude et al., 2014). This number is particularly impressive when considering 
the poor prognosis of relapsed ALL patients. Indeed, relapse after CD19 CAR T cell 
therapy remains a challenge in B-ALL. At this stage of treatment, not only CD19 
positive but also CD19 negative blast cells have been observed and their progression 
is a concern. In a recent trial, target loss occurring under selective pressure was 
observed in one child with relapsed and refractory pre-B-ALL after CD19 CAR T cell 
therapy (Grupp et al., 2013). These results are in accordance with earlier studies 
suggesting that CD19 negative variants are already present at low levels in some 
patients with ALL at the time of treatment (Hotfilder et al., 2005; Sotillo et al., 2015; 
Le Viseur et al., 2009). The CD19 epitope is lost from leukemia cells in 10 to 20% of 
pediatric B-ALL treated with anti-CD19 antibody based therapy (Sotillo et al., 2015). 
The enrichment of CD19 negative blast cells might be a direct consequence of CD19 
CAR therapy leading to a decrease in CD19 CAR T cells efficiency and consequently 
to ALL relapse. To overcome CD19 antigen loss in relapsed ALL patients, alternative 
CAR therapies, targeting new antigens, need to emerge.  
Like CD19, the cell surface antigen CD22 has a B cell restricted expression and is 
essential in B lineage differentiation (Nitschke, 2009; Tedder et al., 2005). Within a 
range of 50 - 100% in adult (Hoelzer and Gökbuget, 2012; Piccaluga et al., 2011; 
Raponi et al., 2011) and around 90% in pediatric acute lymphoblastic leukemia (ALL) 
(Iwamoto et al., 2011; Raetz et al., 2008), CD22 is frequently expressed on B-ALL. 
Complete remission was observed in phase II clinical trials using the humanized anti-
CD22 monoclonal antibody Epratuzumab in combination with chemotherapy in adult 
ALL patients (Advani et al., 2014; Chevallier et al., 2015) and in a phase I dose-
escalation trial of the anti-CD22 recombinant immunotoxin HA22 in relapsed and 
refractory hairy cell leukemia patients (Kreitman et al., 2012). Another anti-CD22 
monoclonal antibody-based therapies, an anti-CD22 CAR (Haso et al., 2013) are 
currently being developed. The CD22 expression profile and the clinical success of 
related therapies confirm CD22 as an important therapeutic target in B cell 
malignancies. 
A therapy based on the currently developed double mutant hCD22 scFv-
(ΔhFc-Δ28BBz) CAR would therefore be an ideal and promising therapeutic option to 
treat CD22 positive pediatric and adult B-ALL patients. This kind of treatment could 
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be used as a single therapy or in combination with CD19 CAR T cells for refractory 
and relapsed ALL patients to overcome the loss of the CD19 epitope (Grupp et al., 
2013). Indeed, this could especially prevent the emergence and growth of CD19 
negative blasts as well as ALL relapse.  
Besides ALL, sustainable remission was also observed in patients with relapsed and 
refractory non-Hodgkin’s lymphoma (NHL), especially with diffuse large B-cell 
lymphoma, when treated with 90Y-epratuzumab tetraxetan, an anti-CD22 
radioimmunotherapy (Kraeber-Bodere et al., 2016; Morschhauser et al., 2010). 
Concerning the treatment of lymphoma with CARs, the clinical efficacy appears more 
modest than for ALL but highly encouraging partial and complete responses were 
observed with CD19 CAR or CD20 CAR therapies (Kochenderfer et al., 2015; Till et 
al., 2008; Wang et al., 2014).  
 
4.2 Evaluation of the hCD22 scFv-(ΔhFc-Δ28BBz) CAR with regard 
to safety 
4.2.1 Stability of the hCD22 and mCD22 targeting domains and derived CARs 
Choosing a selectively expressed tumor target and a single chain variable fragment 
(scFv) with high target affinity is crucial for CAR development as both contribute 
substantially to the safety of such a therapy. The incorporated antibody fragment has 
to specifically recognize its target antigen to avoid off-target toxicity. Another 
important scFv requirement is a high thermal stability (Willuda et al., 1999). Indeed, 
for the use in patients, the activity of the therapeutic antibody fragment has to be 
retained for several hours or days at 37°C in the serum without degradation. 
However, some high affinity scFvs were shown to be unstable with the tendency to 
denature and aggregate, limiting their activity and clinical application (Willuda et al., 
1999; Wörn and Plückthun, 1999). To reduce thermal instability without affecting the 
affinity, a linker peptide or an interdomain disulfide bond can be introduced forming a 
scFv or a stabilized antibody fragment (dsFv), respectively (Wörn and Plückthun, 
2001; Zhao et al., 2011). This stabilization measure was performed for the anti-B3 
immunotoxin B3(dsFv), and, resulted in the prevention of the dissociation of the 
variable chain and reduced the tendency to aggregate (Brinkmann et al., 1993).  
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In the present thesis, a highly stable, humanized anti-CD22 (hCD22) scFv was used 
for the development of an anti-CD22 CAR therapy against CD22 positive leukemia 
and lymphoma. Derived from the clinically established murine anti-CD22 IgG1 RFB4 
antibody (Campana et al., 1985), the hCD22 targeting moiety was generated by 
grafting the specificity-determining regions of the murine RFB4 antibody to a human 
framework, pre-selected for stability from a phage display library (Krauss et al., 
2003b).  
In earlier studies, a disulfide stabilized RFB4 derived anti-CD22 immunotoxin linked 
to PE38, a truncated version of Pseudomonas Exotoxin (PE) was generated 
(Mansfield et al., 1997a). A phase II clinical trial using this anti-CD22 
RFB4(dsFv)-PE38 immunotoxin (called BL22) showed a high response rate with 
complete remissions in patients with hairy cell leukemia (Kreitman et al., 2009). 
A BL22-dsFv derived phage display affinity mutant immunotoxin HA22 showed 
improved binding affinity to CD22 and an enhanced cytotoxic activity in vitro in 
B-lineage ALL cells (Mussai et al., 2010; Salvatore et al., 2002; Wayne et al., 2010). 
To develop anti-CD22 CARs, the scFv portion of HA22, recognizing a proximal 
epitope of CD22 (Ig domain 3) was used as binding domain and compared to a fully 
human, phage display isolated scFv (m971) targeting a more membrane proximal 
epitope (Ig domains 5 - 7). Although the derived CARs mediated anti-tumor activity 
in vitro in ALL cells, a higher therapeutic efficacy was achieved in vivo with the m971 
CAR (Haso et al., 2013). Based on these results, Haso et al., concluded that the 
selection of target antigen epitope has a major impact on CAR efficacy and 
consequently on potent CAR development. However, we hypothesized that the low 
therapeutic activity observed for the HA22 derived CARs in vivo is rather due to a 
biophysical instability of the murine anti-CD22 dsFv, resulting in less antigen binding, 
than due to an inferior epitope accessibility. 
In this context, we investigated the stability of the murine anti-CD22 scFv fragment of 
RFB4 (mCD22) with a linker peptide instead of an interdomain disulfide bond as is 
the case for RFB4(dsFv) included in BL22 and HA22. Surprisingly, both the hCD22 
scFv and the mCD22 scFv displayed the same stability in human serum and PBS 
throughout seven days at 37°C (result 3.1). When expressed in the CAR format with 
either the IgG1 Fc or CD8 spacer domain, CAR T cells with either the mCD22 or the 
hCD22 scFv led to T cell activation (result 3.2). These results demonstrate that 
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antibody fragments (dsFv and scFv) derived from the parental murine anti-CD22 IgG 
display a sufficient stability. Earlier studies also showed the stability of the 
immunotoxin RFB4(scFv)-PE38 after 24 h incubation at 37 °C (Mansfield et al., 
1997b). The disulfide stabilized BL22 showed, similar to the RFB4 IgG, a nine-fold 
improvement in binding affinity to CD22 compared to RFB4(scFv)-PE38 (Reiter et al., 
1996). Taking all together, for the development of BL22, HA22 and derived CARs, 
the disulfide bonds were probably introduced to improve the scFv binding affinities 
and not their stabilities. Furthermore, several studies supported the finding of Haso et 
al., that the efficacy of activated CAR T cells is dependent on the epitope position 
and its distance to the membrane (Hombach et al., 2007; James et al., 2008). To 
further investigate the importance of epitope localization on CD22 CAR T cell 
activation, a direct comparison between the currently developed hCD22 CAR and the 
m971 CAR from Haso et al. could be performed as both scFvs are phage display 
selected but bind different CD22 epitopes. To conclude, despite high thermal stability 
observed for both the hCD22 and mCD22 as scFv but also as CAR, the humanized 
antibody fragment is preferred to its murine counterpart for the development of 
antibody-based therapy. Due to its reduced immunogenicity, the humanized target 
moiety is a safer therapeutic antibody (Kim et al., 2005).  
In previous studies, a strong tendency to aggregate was observed for a CD22 
diabody, derived from the hCD22 scFv, complicating the production and purification 
of this molecule (Krauss et al., 2005b). A decrease in aggregation was obtained by 
engineering the variable heavy (VH) and light (VL) chain interface of the diabody 
resulting in improved antibody solubility and interdomain stability. Since the stability 
of the hCD22 scFv is essential for specific and efficient target binding and 
consequently for full CAR T cell activation, the optimization induced by engineering 
the VH-VL interface of the hCD22 scFv-(ΔhFc-Δ28BBz) CAR was investigated. Taking 
together the results of three independently tested healthy donors, no significant 
improvement in T cell activation was observed for the engineered hCD22 (L36Y) 
scFv-(ΔhFc-Δ28BBz) CAR when compared to the hCD22 scFv-(ΔhFc-Δ28BBz) CAR 
(result 3.4.1.2). The hCD22 scFv-(ΔhFc-Δ28BBz) CAR T cells displayed more 
efficient activation, probably by the higher binding affinity of the wildtype hCD22 scFv 
compared to the engineered hCD22 (L36Y) scFv. In fact, after replacing the leucine 
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residue at position 36 of the variable light chain with tyrosine the binding affinity of 
the engineered hCD22 (L36Y) scFv was reduced by 4,8 fold (Krauss et al., 2005b).  
 
4.2.2 Optimization of hCD22 scFv-(ΔhFc-Δ28BBz) CAR T cell activation by 
mutagenesis 
The large number of developed CD19 CARs and ongoing CD19 CAR phase I and II 
clinical trials treating acute and chronic lymphoblastic leukemia patients confirm the 
success of CAR therapies (Oluwole and Davila, 2016). However, they also reveal the 
need to improve the CAR safety by developing new approaches to continuously 
reduce the CAR T cell induced unspecific toxicity. For their broader use, the risk of 
causing adverse events such as cytokine release syndrome (Tisoncik et al., 2012) or 
“on-target, off-tumor” toxicity (Brentjens et al., 2011b; Lamers et al., 2006; Morgan et 
al., 2010) must be prevented. To enhance clinical CAR efficacy while reducing these 
kind of toxicities, new strategies in CAR design are emerging (Maus and Powell, 
2015). In this context, our newly developed hCD22 scFv-(hFc-28BBz) CAR was 
optimized by mutagenesis to prevent unwanted toxicity. The Fcγ receptors (FcγR) 
binding domain in the IgG1 Fc spacer and of the LCK binding domain in the CD28 
co-stimulatory domain were mutated in the CAR. 
Previous studies showed that for an optimal and full functional CAR T cell response, 
a spacer domain is mandatory for some but not all chimeric immune receptors (Guest 
et al., 2005b; Moritz and Groner, 1995). The Fc spacer, localized between the scFv 
and the transmembrane domain binds target-independently to FcγR expressed on 
innate immune cells (Hombach et al., 2010). This binding causes off-target activation 
of CAR T cells leading to the lysis of monocytes and natural killer cells and cytokine 
release. In addition to these effects, CAR off-target activation might quickly reduce 
anti-tumor activity due to activation-induced cell death. To overcome unspecific CD22 
CAR T cell activation, the domain responsible for FcγR binding in the hFc domain 
was mutated, resulting in the hCD22 scFv-(ΔhFc-28BBz) CAR. IgG1 amino acids 
indispensable for binding IgG1-FcγR were exchanged with IgG2 amino acids 
(Hombach et al., 2010). By mutating this region, the interaction of the hCD22 scFv-
(ΔhFc-28BBz) and the double mutated hCD22 scFv-(ΔhFc-Δ28BBz) CAR T cells with 
FcγR+ THP-1 cells and the target independent activation of these cells could be 
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successfully prevented (result 3.3.2.1). Consequently, our results obtained for both 
hCD22 CAR variants confirmed those achieved with an anti-CD30 CAR presenting 
the same mutated FcγR binding domain (Hombach et al., 2010). Most importantly, 
the introduced hFc mutation had no impact on the efficacy of CD22 CAR T cell 
activation as observed for three individual donors (result 3.3.2.3).  
The co-stimulatory domain CD28 is required for full CAR T cell activation, 
characterized by enhanced anti-tumor activity and cytokine release such as IFNγ and 
IL-2 as well as improved proliferation and persistence of CAR T cells, both in vitro 
and in vivo (Kowolik et al., 2006; Maher et al., 2002; Savoldo et al., 2011). 
Furthermore, CD28 co-stimulatory domain is essential for the activation-induced 
interleukin-2 (IL-2) secretion (Hombach et al., 2001b) which plays an important role in 
the maintenance of regulatory T (T reg) cells (Brandenburg et al., 2008; Thornton et 
al., 2004). It has been previously demonstrated that the anti-tumor activity of 
CD28-CD3ζ CAR T cells, attended by a rising amount of tumor infiltrating T reg cells, 
is less efficient compared to CD3ζ CAR T cells (Kofler et al., 2011). It was shown that 
mutating the CD28 binding domain of the LCK enzyme blocks IL-2 secretion in vitro 
without affecting T cell specific tumor cell lysis and IFNγ release, induced by 
activated CAR T cells (Kofler et al., 2011).  
Our results confirm these observations using three healthy donors demonstrating that 
for the hCD22 scFv-(hFc-Δ28BBz) and the double mutated hCD22 scFv-
(ΔhFc-Δ28BBz) CAR T cells, the introduced CD28 mutation did not alter the ability to 
induce specific tumor cell lysis and IFNγ release (result 3.3.2.3). Unexpectedly, no 
IL-2 secretion was observed for these two hCD22 CAR variants, however, we 
surprisingly also found an IL-2 abolishment for the parental and the hCD22 scFv-
(ΔhFc-28BBz) CAR T cells as well as for parental CEA CAR T cells (result 3.3.2.2). 
Several studies confirmed the variability of IL-2 secretion by CAR T cells including 
the CD28 and 4-1BB domain. Indeed, for CD19 CAR T cells harboring the same 
intracellular regions, the amount of produced IL-2 was different from donor to donor 
(Tammana et al., 2010). Although the IFNγ release is consistent, only CD19 CAR 
T cells from two donors released IL-2 whereas effector cells from a third donor lacked 
IL-2 secretion after activation by CD19 positive Daudi cells. The absence of IL-2 
release was also observed in two other studies, using third generation CAR T cells 
(with CD28 and 4-1BB) targeting either mesothelin or the CD22 antigen (Carpenito et 
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al., 2009; Haso et al., 2013). Furthermore, for the mesothelin CAR as well as for 
another third generation CD19 CAR also including CD28 and 4-1BB, transduced 
CD4+ and CD8+ T cells were analyzed separately, demonstrating that only CD4+ CAR 
T cells were able to induce IL-2 secretion while no cytokine release was observed for 
CD8+ CAR T cells (Carpenito et al., 2009; Milone et al., 2009). For T cell cultivation, 
we used X-Vivo 20 medium which sustains the proliferation of CD8+ T cells but not of 
CD4+ T cells. This might influence the IL-2 levels observed for activated parental and 
mutated hCD22 scFv-(ΔhFc-28BBz) CAR T cells. However, this would rather explain 
a decrease in IL-2 secretion than a full suppression of this cytokine. High amounts of 
IL-2 were produced by T cells transduced with a CEA CAR harboring CD28 and the 
co-stimulatory OX40 domain instead of 4-1BB (Hombach and Abken, 2011). 
Nevertheless, in this study, while IFNγ was secreted, no IL-2 release was observed 
for second generation CEA CAR T cells including only OX40, thus demonstrating that 
this co-stimulatory domain has no impact on IL-2 release (Hombach and Abken, 
2011). Since our results (result 3.3.2.2.1) confirmed the observation of Hombach and 
Abken concerning the activation-induced IL-2 release of T cells carrying the third 
generation CEA CAR including the CD28 and OX40 domains, this CAR was taken as 
reference for the following experiment. By replacing the co-stimulatory domain 4-1BB 
of our parental hCD22 CAR with OX40 while keeping the CD28 domain responsible 
for IL-2 secretion, activation-induced production of IL-2 could be observed (result 
3.3.2.2.2). As a next step, to confirm the observations of Kofler et al., it would be 
interesting to investigate if by mutating the CD28 LCK binding domain in the hCD22 
CAR variant with CD28 and OX40, IL-2 release could be blocked after CAR T cell 
activation. 
T reg cells are necessary to sustain immune cell homeostasis by regulating other 
immune cells in a dominant negative fashion. In fact, T reg cells prevent autoimmune 
diseases by suppressing immune responses to tumor, allo- and autoantigens. 
However, they are also able to suppress T cell proliferation in vitro and in vivo 
(Shevach, 2002) thus acting against T cell persistence, proliferation and activation on 
which CAR therapies are based. The amount and the functions of T reg cells need to 
be controlled. Interleukin-2 cytokine is essential for the peripheral balance of T reg 
cells by mediating their survival and for the activation of their T cell suppressive 
function (Brandenburg et al., 2008; Thornton et al., 2004). Maintaining a low number 
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of T reg cells by blocking the secretion of IL-2 by mutating the CD28 LCK binding 
domain of the CAR is therefore of therapeutic relevance for CAR therapies. In the 
presence of T reg cells, an enhanced anti-tumor response was obtained in vivo for 
mutated CD28 CAR T cells compared to parental CAR T cells (Kofler et al., 2011). In 
this context, even if IL-2 is absent for all types of hCD22 CAR T cells with 4-1BB as 
co-stimulatory domain, the CD28 mutation was kept in the selected lead candidate to 
ensure the highest level of safety in further studies. Since the Fc and CD28 
mutations, introduced for safety and efficacy reasons, did not affect the ability to 
induce CAR T cell activation, the hCD22 scFv-(ΔhFc-Δ28BBz) CAR, was selected as 
lead candidate. This CAR displayed efficient CAR T cell activation and its lack of 
activation-induced IL-2 release suggests excellent properties for preclinical and 
clinical development.  
To assess the therapeutic efficacy of double mutant hCD22 scFv-(ΔhFc-Δ28BBz) 
CAR T cells in vivo, the NOD/SCID mouse model was chosen based on earlier 
results demonstrating the successful engraftment of the human acute lymphoblastic 
leukemia (ALL) cell line Nalm-6 in SCID mice with 1*106 cells (Seifert et al., 2008). 
Since improved engraftment of human cells was observed in NOD/SCID mice 
compared to SCID mice (Belizário, 2009; Greiner et al., 1998), NOD/SCID mice were 
chosen as a suitable model for hCD22 CAR T cells in vivo studies. Surprisingly, no 
ALL leukemia engraftment was observed in NOD/SCID mice even with a high 
amount of Nalm-6-luciferase tumor cells (5*106 cells) (result 3.4.3). The 
NOD/SCID/Gamma mouse model (NSG), corresponding to a hybrid model crossing 
NOD/SCID mice with IL2rg-/- deficient mice, features an improved efficacy for human 
tumor cell engraftment (Ishikawa et al., 2005; Ito et al., 2002). In this model, leukemia 
xenograft transplantation could be performed by injection of 1*106 Nalm-6 luciferase 
cells (Barrett et al., 2011). In this study, for the control group lacking treatment, fatal 
leukemia was observed after 22 to 25 days and the disease was reliably detected by 
bioluminescence imaging seven days after tumor cell injection. This confirmed that 
Nalm-6 luciferase cells could be used for leukemia engraftment whereas the 
NOD/SCID mouse model might not be suitable for this xenograft transplantation. 
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4.3 Conclusion and outlook 
Within the present thesis, four distinct humanized CD22 CARs were developed to 
treat CD22 positive leukemia and lymphoma. Optimization by mutating the FcRγ and 
LCK binding domain was performed to prevent adverse events caused by unwanted 
toxicities while maintaining successful and specific hCD22 CAR T cell activation. 
Because of its efficient T cell activation, its high tumor specific cytotoxicity and its 
reduced immunogenicity, the double mutated hCD22 scFv-(ΔhFc-Δ28BBz) CAR 
constitutes a promising effector molecule for potential clinical applications as a novel 
CD22-targeted CAR therapy.  
The upcoming preclinical study in a suitable xenograft mouse model, will give us 
information about the in vivo efficacy of hCD22 scFv-(ΔhFc-Δ28BBz) CAR T cells. 
A complementary safety check of this therapy will be further performed in transgenic 
mice expressing the human CD22 antigen to investigate potential cross reactivity. To 
further reduce CAR toxicity effects, several emerging strategies in CAR design to turn 
off conventional CAR T cells might be applicable. Switching CAR T cells on and off 
can be performed, for example, by introducing an engineered hinge domain into the 
CAR (Juillerat et al., 2016) or by using the UniCAR system in which external specific 
scFv-epitope molecules are added to modulate the activity of a permanent 
anti-epitope CAR (Cartellieri et al., 2016).  
Due to the B cell lineage restricted expression profile of CD22, this anti-CD22 
antibody based CAR therapy represents a promising alternative to currently 
investigated CD19 CAR T cell therapies (Khalil et al., 2016). A CD22 CAR therapy 
could also be used in combination with a previous CD19 CAR treatment for CD19 
negative refractory and relapsed ALL patients who retained the expression of CD22. 
While the present thesis focused on the development of a new CAR therapy for 
CD22 positive leukemia and lymphoma, this approach might be extended to treat 
other CD22 expressing tumors including solid tumors such as lung cancers (Tuscano 
et al., 2012).  
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Figure 24: Map of the entry vector pENTR.  
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Figure 25: Map of the lentiviral vector pRRL.  
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Figure 26: Map of the lentiviral helper plasmid #1. 
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Figure 27: Map of the lentiviral helper plasmid #2. 
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Figure 28: Map of the subcloning vector pEUC6B. 
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Figure 29: Map of the mammalian expression vector pEE12.4. 
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